

Asymmetric Syntheses of (–)-3-*epi*-Fagomine, (2*R*,3*S*,4*R*)-Dihydroxypipelicolic Acid, and Several Polyhydroxylated Homopipelicolic Acids


Kristína Csatayová,[†] Stephen G. Davies,^{*,†} Ai M. Fletcher,[†] J. Gair Ford,[‡] David J. Klauber,[‡] Paul M. Roberts,[†] and James E. Thomson[†]

[†]Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.

[‡]AstraZeneca Pharmaceutical Development, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, U.K.

Supporting Information

ABSTRACT: A range of enantiopure polyhydroxylated piperidines, including (2*R*,3*S*,4*R*)-dihydroxypipelicolic acid, (–)-3-*epi*-fagomine, (2*S*,3*S*,4*R*)-dihydroxyhomopipelicolic acid, (2*S*,3*R*,4*R*)-dihydroxyhomopipelicolic acid, and two trihydroxy-substituted homopipelicolic acids, have been prepared using diastereoselective olefinic oxidations of a range of enantiopure tetrahydropyridines as the key step. The requisite substrates were readily prepared from *tert*-butyl sorbate using our diastereoselective hydroamination or aminohydroxylation protocols followed by ring-closing metathesis. After diastereoselective olefinic oxidation of the resultant enantiopure tetrahydropyridines and deprotection, enantiopure polyhydroxylated piperidines were isolated as single diastereoisomers (>99:1 dr) in good overall yield.



INTRODUCTION

Polyhydroxylated piperidines, which are also known as iminosugars, are produced as secondary metabolites in a vast array of different organisms, although the majority originate in plants.¹ The structures of (+)-1-deoxynojirimycin **1**, (+)-fagomine **2**, and hydroxy-substituted pipelicolic acids such as **3** and **4** are representative of this class of natural products.^{2,3} Their structural similarity to monosaccharides means that they can act as potent substrate mimics for a variety of glycosidases, and this often potent biological activity has spurred research into both the synthesis of polyhydroxylated piperidines and their application as therapeutic agents.⁴ In addition to displaying desirable biological activity,⁵ pipelicolic acid and its derivatives are often substituted for proline in conformational and ligand-binding studies of biologically active peptides and foldamers.⁶

As part of our ongoing research program directed toward the *de novo* preparation of imino- and aminosugars and their derivatives,⁷ we decided to investigate the synthesis of a range of polyhydroxylated piperidines, including fagomines **8** ($Z = \text{CH}_2$), dihydroxypipelicolic acids **8** ($Z = \text{CO}$), and their corresponding homopipelicolic acids **9** ($Y = \text{H}, \text{OH}$), via the diastereoselective dihydroxylation of enantiopure tetrahydropyridines **7** ($Y = \text{H}, \text{OH}$). It was envisaged that the requisite tetrahydropyridine substrates **7** ($Y = \text{H}, \text{OH}$) could be prepared using our lithium amide conjugate addition methodology⁸ for the hydroamination or aminohydroxylation of a dienyl ester **5** followed by ring-closing metathesis of the resultant β -amino ester **6** ($X = \text{H}$) or α -hydroxy- β -amino ester **6** ($X = \text{OH}$),

respectively. Subsequent diastereoselective *syn*-dihydroxylation (using either Upjohn⁹ or Donohoe¹⁰ protocols) or *anti*-dihydroxylation (using our chemoselective olefinic oxidation^{7a,b,d,11} procedure) of these tetrahydropyridine substrates **7** would then give the target compounds after elaboration/deprotection (Figure 1).

RESULTS AND DISCUSSION


Conjugate addition of lithium (*R*)-*N*-(but-3-en-1-yl)-*N*-(α -methylbenzyl)amide **11** to dienyl ester **10** (which was produced in 80% yield upon esterification of commercially available sorbic acid) followed by treatment of the resultant lithium (*Z*)- β -amino enolate¹² with either saturated aq NH_4Cl or (–)-camphorsulfonyloxaziridine [(–)-CSO] produced the known β -amino ester **12**¹³ in 69% yield (>99:1 dr) or α -hydroxy- β -amino ester **13** in 64% yield (>99:1 dr), respectively. The stereochemical outcomes of these reactions were initially assigned by reference to our transition-state mnemonic¹⁴ for the conjugate addition reaction and by analogy to the well-established outcomes of these hydroamination and aminohydroxylation protocols.^{8,15} Subsequent ring-closing metathesis of both **12** and **13** with Grubbs I catalyst gave tetrahydropyridines **14**¹³ and **15** in 74 and 76% yield, respectively, as single diastereoisomers (>99:1 dr) in each case. Transesterification of **14** and **15** upon treatment with SOCl_2 and MeOH gave the

Received: August 22, 2014

Published: October 22, 2014

with 1.0 M aq HCl to remove the acetonide protecting group, giving **26** in 26% yield (from **24**, 60:40 dr). An alternative protecting group strategy was then employed in an effort to prevent epimerization from occurring during the oxidation process. Hydrogenolytic N-deprotection of **24** in the presence of Boc₂O gave *N*-Boc-substituted piperidine **27** in 48% yield (>99:1 dr). Subsequent oxidative cleavage of the 1,2-diol unit¹⁹ within **27**, further oxidation of the resultant aldehyde, and acid-catalyzed deprotection of the acetonide group gave (2*R*,3*S*,4*R*)-dihydroxypipelic acid **28** in 67% yield (>99:1 dr) (Scheme 4).

Scheme 4




Diol **24** was also elaborated to (-)-3-*epi*-fagomine **31** via a three-step procedure: Oxidative cleavage of the 1,2-diol unit within **24** upon treatment with NaIO₄ and reduction of the resultant aldehyde with NaBH₄ gave **29** in 62% yield (>99:1 dr). Deprotection of **29** was achieved by hydrogenolysis to give **30**. Then, acid-catalyzed hydrolysis of the acetonide group within **30** gave (-)-3-*epi*-fagomine **31** as a single diastereoisomer (>99:1 dr) in 80% overall yield (Scheme 5). The spectroscopic data and specific rotation of **31** were in excellent agreement with literature values: [α]_D²⁰ - 72.2 (c 1.0, H₂O); lit.^{20e} for *ent*-**31**, [α]_D²⁶ + 74.4 (c 0.95, H₂O); and lit.²¹ for *ent*-**31**, [α]_D + 69 (c 0.5, H₂O).


Under Donohoe¹⁰ conditions, *syn*-dihydroxylation of **15** gave a single osmate ester-TMEDA complex **32** (>99:1 dr). After treatment of **32** with P(CH₂OH)₃, Et₃N, and silica gel,¹⁶ triol **22** was isolated in 87% yield (from **15**, >99:1 dr). Hydrolysis of the ester moiety within **22** gave carboxylic acid **33** in 60% yield (>99:1 dr). However, this compound was found to be fairly insoluble, and hydrogenolytic deprotection of **33** was therefore not possible. However, hydrogenolysis of **22** proceeded efficiently to give **34** in quantitative yield (>99:1 dr). Subsequent hydrolysis of **34** gave polyhydroxy-substituted homopipelic acid **35** in 80% yield (>99:1 dr) (Scheme 6).

Attempted *anti*-dihydroxylation of tetrahydropyridine **14** under our chemo- and diastereoselective olefinic oxidation

Scheme 5




Scheme 6



procedure^{7a,b,d,11} (i.e., treatment of the unsaturated amine with CCl₃CO₂H followed by *m*-CPBA) produced a 34:56:10 mixture of **36**, **37**, and **38**, respectively. Purification of the crude reaction mixture allowed the isolation of lactone **36** [ν_{max} : 1773 cm⁻¹ (C=O)] in 12% yield (>99:1 dr), diol **37** in 15% yield (>99:1 dr), and diol **38** in 7% yield (>99:1 dr) (Scheme 7). The relative configuration within **37** was established unambiguously via single crystal X-ray diffraction analysis,¹⁷ and the absolute (2'*S*,3'*R*,4'*R*, α *R*)-configuration of **37** was assigned by reference to the known (*R*)-configuration of the α -methylbenzyl fragment. The configuration within lactone **36** was next established by chemical correlation upon treatment of diol **37** with aqueous HBF₄ in CH₂Cl₂, which promoted complete conversion to lactone **36** as a single diastereoisomer (>99:1 dr); following chromatographic purification, **36** was isolated in 41% yield (>99:1 dr). Reaction of diol **38** under the same conditions gave a 70:30 mixture of lactones **39** and **40**, which were isolated in 70 and 29% yield, respectively, as single diastereoisomers (>99:1 dr) in each case (Scheme 7). The structure of lactone **40** was established by ¹H-¹³C NMR HMBC spectroscopic analysis and from the diagnostic value of the C=O absorbance in the infrared spectrum [ν_{max} : 1785

Scheme 7




cm^{-1} ($\text{C}=\text{O}$)]. The relative configuration within **39** [ν_{max} : 1739 cm^{-1} ($\text{C}=\text{O}$)] was established unambiguously via single crystal X-ray diffraction analysis,¹⁷ and the absolute (1*S*,5*S*,9*S*, α *R*)-configuration of **39** was assigned by reference to the known (*R*)-configuration of the α -methylbenzyl fragment. Furthermore, the determination of a Flack x parameter¹⁸ of $-0.09(17)$ for the structure of **39** confirmed its assigned absolute configuration, and therefore also those of **38** and **40**.

Repeating the oxidation reaction with TsOH as the Brønsted acid reagent produced a 56:44 mixture of lactones **36** and **42**, which were isolated in 23 and 37% yield, respectively (>99:1 dr for both). The identity of **42** was confirmed unambiguously via chemical correlation: Treatment of an authentic sample of **36** with TsCl and pyridine gave **42** as the sole reaction product, which was isolated in 49% yield (>99:1 dr) after chromatographic purification. Employing aqueous HBF_4 as the Brønsted acid reagent produced only lactone **36** upon oxidation of either tetrahydropyridine **14** ($\text{R} = \text{tBu}$) or **16** ($\text{R} = \text{Me}$), giving **36** as a single diastereoisomer (>99:1 dr) in 41 or 32% yield, respectively (Scheme 8). The formation of tosylate **42** is consistent with a mechanism whereby epoxidation of tetrahydropyridine **14** occurs on the 3*Si*,4*Re* face²² (i.e., the upper face as drawn) followed by regioselective ring-opening of intermediate epoxide **41** with tosylate at the C(4)-position and lactonization of the resultant alcohol to give lactone **42**; lactone **36** can be formed via a similar process in which intermediate epoxide **41** is attacked at the C(4)-position by H_2O .


In support of this mechanistic hypothesis, an authentic sample of epoxide **44** was prepared from lactone **36** and independently treated with aqueous HBF_4 under conditions analogous to those employed during the olefinic oxidation of tetrahydropyridines **14** and **16**. Initially, mesylation of the hydroxyl group within **36** gave mesylate **43** in 77% yield (>99:1 dr), and subsequent treatment of **43** with K_2CO_3 in MeOH then effected methanolysis of the lactone and base-induced epoxide formation to give **44** as a single diastereoisomer (>99:1 dr) in 36% isolated yield. Treatment of this authentic sample of epoxide **44** with aqueous HBF_4 promoted the exclusive

Scheme 8



formation of lactone **36**, which was isolated in 50% yield (>99:1 dr) after purification of the crude reaction mixture (Scheme 9). This result is therefore consistent with the intermediacy of epoxide **44** in the formation of lactone **36** upon olefinic oxidation of tetrahydropyridine **16**.


Scheme 9



Next, attempts were made to isolate the corresponding epoxides directly upon oxidation of tetrahydropyridines **14** and **16** with $\text{CF}_3\text{CO}_3\text{H}$ [prepared in situ from UHP and $(\text{CF}_3\text{CO})_2\text{O}$]. Oxidation of **16** gave a 63:37 mixture of lactone **36** and epoxide **44**, whereas oxidation of **14**, after workup, gave a 29:26:45 mixture of lactone **36**, epoxide **41**, and diol **37**, respectively. Unfortunately, attempts to correlate the stereochemistries between epoxides **41** and **44** upon transesterification of **41** were not successful as only decomposition of **41** was observed; the configuration of **41** was therefore assigned by analogy to that of **44**. This authentic sample of **41** was treated with aqueous HBF_4 under conditions analogous to those employed during the olefinic oxidation of tetrahydropyridine **14** and was found to give lactone **36** exclusively; after purification of the crude reaction mixture, **36** was isolated in 48% yield (>99:1 dr). This result is therefore also consistent with the intermediacy of epoxide **41** in the formation of lactone **36** upon olefinic oxidation of tetrahydropyridine **14** (Scheme 10).


Finally, removal of the *N*- α -methylbenzyl group within **36** via hydrogenolytic deprotection in the presence of $\text{Pd}(\text{OH})_2/\text{C}$

Scheme 10



gave quantitative conversion to **45**; standing a solution of **45** in H_2O for two days effected hydrolysis to give the zwitterionic β -amino acid **46**. Purification of **46** by ion exchange chromatography on Dowex 50WX8 resin gave (2*S*,3*R*,4*R*)-dihydroxyhomopipicolinic acid **46** as a single diastereoisomer (>99:1 dr) in quantitative yield (Scheme 11). The relative

Scheme 11




configuration within **46** was confirmed unambiguously via single crystal X-ray diffraction analysis,¹⁷ and the determination of a Flack α parameter¹⁸ of 0.1(2) for the structure of **46** confirmed the assigned absolute (2*S*,3*R*,4*R*)-configuration of **46**, and therefore also those of **36** and **45**.

Olefinic oxidation of the analogous hydroxy-bearing tetrahydropyridine **15** in the presence of $\text{CCl}_3\text{CO}_2\text{H}$ gave an inseparable 87:13 mixture of lactone **47** and triol **48** (of undetermined relative configuration), respectively. However, repetition of the reaction employing TsOH as an alternative Brønsted acid reagent gave lactone **47** exclusively; the corresponding tosylate **49** was not observed in this case. After purification of the crude reaction mixture, we isolated **47** in 23% yield (>99:1 dr) (Scheme 12). The relative configuration within **47** was then established unambiguously via single crystal X-ray diffraction analysis,¹⁷ and the absolute (2*R*,3*S*,4*R*,5*R*, α *R*)-configuration of **47** was assigned by reference to the known (*R*)-configuration of the α -methylbenzyl fragment. The addition of a hydroxyl group does not therefore perturb the high diastereoselectivity observed in the epoxidation of these tetrahydropyridines.

Following the oxidation of tetrahydropyridine **15** in the presence of aqueous HBF_4 , lactone **47** and trihydroxy β -amino acid **50** were isolated in 47 and 20% yield, respectively (>99:1 dr for each). The identity of **50** was confirmed by chemical correlation to lactone **47** upon treatment of an aliquot with $\text{CF}_3\text{CO}_2\text{H}$, which promoted quantitative conversion to **47**. Oxidation of tetrahydropyridine **17** under identical conditions

Scheme 12




gave lactone **47** as the only isolable product in 20% yield (>99:1 dr). Both **50** and **47** were then converted into polyhydroxy-substituted homopipicolinic acid **51**. Hydrogenolytic *N*-deprotection of **50** in the presence of $\text{Pd}(\text{OH})_2/\text{C}$ gave **51** in quantitative yield after purification via ion exchange chromatography on Dowex 50WX8 resin. Similarly, hydrogenolysis of **47** followed by standing a solution of **52** in H_2O at rt for two days gave **51** in quantitative yield (>99:1 dr) (Scheme 13).

CONCLUSION

In conclusion, the asymmetric syntheses of (2*R*,3*S*,4*R*)-dihydroxypipicolinic acid, (–)-3-*epi*-fagomine, (2*S*,3*S*,4*R*)-dihydroxyhomopipicolinic acid, (2*S*,3*R*,4*R*)-dihydroxyhomopipicolinic acid, and two trihydroxy-substituted homopipicolinic acids have been achieved in good yield and high diastereoisomeric purity. Conjugate addition of lithium (*R*)-*N*-(but-3-en-1-yl)-*N*-(α -methylbenzyl)amide to *tert*-butyl sorbate followed by treatment of the resultant lithium (*Z*)- β -amino enolate with either saturated aq NH_4Cl or (–)-camphorsulfonyloxaziridine gave the corresponding enantiopure β -amino ester or α -hydroxy- β -amino ester, respectively. Subsequent ring-closing metathesis constructed the requisite tetrahydropyridine scaffold. Olefinic oxidations of these enantiopure tetrahydropyridines proceeded with extremely high diastereoselectivity to give *syn*- or *anti*-diols (or the corresponding lactones). Following deprotection, enantiopure polyhydroxylated piperidines were all prepared as single diastereoisomers (>99:1 dr) in good overall yield.

Scheme 13



EXPERIMENTAL SECTION

General Experimental Details. All reactions involving organometallic or other moisture-sensitive reagents were carried out under a nitrogen atmosphere using standard vacuum line techniques and glassware that was flame-dried and cooled under nitrogen before use. Solvents were dried according to the procedure outlined by Grubbs and co-workers.²³ BuLi was purchased as a solution in hexanes and titrated against diphenylacetic acid before use. All other reagents were used as supplied without prior purification. Organic layers were dried over Na₂SO₄. Thin layer chromatography was performed on aluminum plates coated with 60 F₂₅₄ silica. Plates were visualized using UV light (254 nm), 1% aq KMnO₄, or Dragendorff's reagent. Flash column chromatography was performed on Kieselgel 60 silica. Melting points are uncorrected. Specific rotations are reported in 10⁻¹ deg cm² g⁻¹ and concentrations in g/100 mL. IR spectra were recorded using an ATR module. Selected characteristic peaks are reported in cm⁻¹. NMR spectra were recorded in the stated deuterated solvent. Spectra were recorded at rt unless otherwise stated. The field was locked by external referencing to the relevant deuterium resonance. When the diastereotopic methyl groups of acetamide functionalities could not be unambiguously assigned, the descriptor *MeCMe* was employed. ¹H–¹H COSY, ¹H–¹³C HMQC, and ¹H–¹³C HMBC analyses were used to establish atom connectivity. Accurate mass measurements were run on a TOF spectrometer internally calibrated with polyalanine.

X-ray Crystal Structure Determination.¹⁷ Data were collected using either graphite-monochromated Mo K α (for 37) or Cu K α (for 21·H₂O, 23, 39, 46, and 47) radiation using standard procedures at 150 K. The structure was solved by direct methods (SIR92); all non-hydrogen atoms were refined with anisotropic thermal parameters. Hydrogen atoms were added at idealized positions. The structure was refined using the CRYSTALS program.²⁴

(R)-N-(But-3-en-1-yl)-N-(α -methylbenzyl)amine. 4-Bromobut-1-ene (75.0 g, 555 mmol) was added to a stirred mixture of (R)- α -methylbenzylamine (177 mL, 1.39 mol, >99% ee) and K₂CO₃ (92.1 g, 666 mmol) at rt, and the resultant mixture was heated at 50 °C for 12 h. The reaction mixture was allowed to cool to rt. H₂O (1.5 L) and Et₂O (1.5 L) were added, and the aqueous layer was extracted with Et₂O (2 \times 750 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent 30–40 °C petrol/Et₂O/NEt₃, 30:70:1) gave (R)-N-(but-3-en-1-yl)-N-(α -methylbenzyl)amine as a yellow oil (65.8 g, 68%, >99:1 dr):²⁵ [α]_D²⁰ + 42.1 (c 1.0, CHCl₃), lit.²⁵ [α]_D²⁵ + 41.6 (c 1.0, CHCl₃); δ _H (400 MHz, CDCl₃) 1.36 (3H, d, J = 6.6 Hz, C(α)Me),

2.24–2.34 (2H, m, C(2)H₂), 2.54–2.70 (2H, m, C(1)H₂), 3.77 (1H, q, J = 6.6 Hz, C(α)H), 5.06–5.19 (2H, m, C(4)H₂), 5.75–5.91 (1H, m, C(3)H), 7.22–7.36 (5H, m, Ph).

tert-Butyl (E,E)-Hexa-2,4-dienoate [tert-Butyl Sorbate] 10. Condensed isobutene (60 mL) at –78 °C was added to a stirred solution of sorbic acid (10.0 g, 89.2 mmol) and concd aq H₂SO₄ (1.0 mL) in CH₂Cl₂ (200 mL) at 0 °C, and the resultant mixture was stirred at 0 °C for 1 h. The reaction mixture was then allowed to warm to rt and stirred for 48 h. The reaction mixture was then washed with saturated aq NaHCO₃ (5 \times 100 mL), and the combined aqueous washings were extracted with CH₂Cl₂ (2 \times 100 mL). The combined organic extracts were washed with brine (100 mL), dried, and concentrated in vacuo. Purification via flash column chromatography (eluent 30–40 °C petrol/Et₂O, 50:1) gave 10 as a colorless oil (12.0 g, 80%, >99:1 dr):^{7c} δ _H (400 MHz, CDCl₃) 1.49 (9H, s, CMe₃), 1.85 (3H, d, J = 6.2 Hz, C(6)H₃), 5.71 (1H, d, J = 15.4 Hz, C(2)H), 6.07–6.21 (2H, m, C(4)H, C(5)H), 7.14 (1H, dd, J = 15.4, 10.0 Hz, C(3)H).

tert-Butyl (3S,4R,4E)-3-[N-But-3'-enyl-N-(α -methylbenzyl)amino]hex-4-enoate 12. BuLi (2.40 M in hexanes, 11.5 mL, 27.6 mmol) was added dropwise to a stirred solution of (R)-N-(but-3-en-1-yl)-N-(α -methylbenzyl)amine (5.00 g, 28.6 mmol, >99:1 er) in THF (20 mL) at –78 °C. After this mixture was stirred for 30 min, a solution of 10 (3.00 g, 17.8 mmol, >99:1 dr) in THF (5 mL) at –78 °C was added dropwise via a cannula. The reaction mixture was left to stir at –78 °C for 2 h, and then saturated aq NH₄Cl (10 mL) was added. The resultant mixture was allowed to warm to rt and stirred for 15 min, and then concentrated in vacuo. The residue was partitioned between CH₂Cl₂ (200 mL) and H₂O (100 mL), and the aqueous layer was extracted with CH₂Cl₂ (2 \times 200 mL). The combined organic extracts were washed sequentially with 10% aq citric acid (200 mL) and saturated aq NaHCO₃ (200 mL), and then dried and concentrated in vacuo. Purification via flash column chromatography (eluent isohexane/EtOAc, 8:1) gave 12 as a pale yellow oil (4.23 g, 69%, >99:1 dr):¹³ [α]_D²⁰ – 14.6 (c 1.0, CHCl₃), lit.¹³ [α]_D²⁴ – 11.3 (c 2.5, CHCl₃); δ _H (400 MHz, CDCl₃) 1.37 (3H, d, J = 6.8 Hz, C(α)Me), 1.41 (9H, s, CMe₃), 1.71 (3H, d, J = 5.4 Hz, C(6)H₃), 1.99–2.09 (2H, m, C(2')H₂), 2.29 (1H, dd, J = 14.1, 8.4 Hz, C(2)H_A), 2.42 (1H, dd, J = 14.1, 6.6 Hz, C(2)H_B), 2.48–2.58 (2H, m, C(1')H₂), 3.77–3.81 (1H, m, C(3)H), 3.94 (1H, q, J = 6.8 Hz, C(α)H), 4.88–4.94 (2H, m, C(4')H₂), 5.50–5.53 (2H, m, C(4)H, C(5)H), 5.65 (1H, ddt, J = 17.1, 10.3, 6.9 Hz, C(3')H), 7.19–7.39 (5H, m, Ph).

tert-Butyl (R,R,R,E)-2-Hydroxy-3-[N-but-3'-enyl-N-(α -methylbenzyl)amino]hex-4-enoate 13. BuLi (2.40 M in hexanes, 11.5 mL, 27.6 mmol) was added dropwise to a stirred solution of (R)-N-(but-3-en-1-yl)-N-(α -methylbenzyl)amine (5.00 g, 28.6 mmol, >99:1 er) in THF (20 mL) at –78 °C. After the mixture was stirred for 30 min, a solution of 10 (3.00 g, 17.8 mmol, >99:1 dr) in THF (5 mL) at –78 °C was added dropwise via a cannula. The reaction mixture was left to stir at –78 °C for 2 h, and then (–)-CSO (6.95 g, 30.3 mmol) was added. The resultant mixture was allowed to warm to rt over 12 h and then concentrated in vacuo. The residue was dissolved in CH₂Cl₂ (150 mL), and the resultant solution was washed sequentially with 10% aq citric acid (200 mL) and saturated aq NaHCO₃ (200 mL), and then dried and concentrated in vacuo. Purification via flash column chromatography (eluent isohexane/EtOAc, 6:1) gave 13 as a pale yellow oil (4.12 g, 64%, >99:1 dr): [α]_D²³ – 82.7 (c 1.0, CHCl₃); ν _{max} (ATR) 3500 (O–H), 1724 (C=O), 1640 (C=C); δ _H (400 MHz, CDCl₃) 1.35 (3H, d, J = 6.8 Hz, C(α)Me), 1.49 (9H, s, CMe₃), 1.70 (3H, d, J = 6.1 Hz, C(6)H₃), 2.00–2.15 (2H, m, C(2')H₂), 2.59–2.64 (1H, m, C(1')H_A), 2.77 (1H, ddd, J = 13.9, 9.5, 6.6 Hz, C(1')H_B), 3.49 (1H, dd, J = 9.0, 3.5 Hz, C(3)H), 4.08 (1H, d, J = 3.5 Hz, C(2)H), 4.19 (1H, q, J = 6.8 Hz, C(α)H), 4.92–4.97 (2H, m, C(4')H₂), 5.50–5.69 (3H, m, C(4)H, C(5)H, C(3')H), 7.22–7.42 (5H, m, Ph); δ _C (100 MHz, CDCl₃) 14.6 (C(α)Me), 18.0 (C(6)), 28.0 (CMe₃), 34.9 (C(2')), 46.7 (C(1')), 57.2 (C(α)), 64.6 (C(3)), 73.4 (C(2)), 81.7 (CMe₃), 115.6 (C(3')), 126.7 (C(4)), 127.7, 128.0, 128.7 (*o,m,p*-Ph), 129.8 (C(5)), 136.9 (C(4')), 144.3 (*i*-Ph), 172.2 (C(1)); *m/z* (ESI⁺) 360 ([M + H]⁺, 100%);

HRMS (ESI⁺) C₂₂H₃₃NNaO₃⁺ ([M + Na]⁺) requires 382.2353, found 382.2346.

tert-Butyl (2'S,αR)-2-[N(1')-(α-Methylbenzyl)-1',2',5',6'-tetrahydropyridin-2'-yl]ethanoate 14. Grubbs I catalyst (638 mg, 1.02 mmol) was added to a stirred solution of **12** (3.50 g, 10.2 mmol, >99:1 dr) in anhydrous, degassed CH₂Cl₂ (400 mL) at rt. The resultant mixture was stirred at 40 °C for 48 h and then concentrated in vacuo. The residue was dissolved in CH₂Cl₂ (150 mL). The resultant solution was stirred at rt, and P(CH₂OH)₃²⁶ (12.6 g, 102 mmol) and Et₃N (2.84 mL, 20.4 mmol) were added sequentially. The resultant mixture was stirred at rt for 5 min. Then, excess silica gel (~8 g) was added, and stirring was continued for 12 h. The reaction mixture was then concentrated in vacuo. Purification via flash column chromatography (eluent isohexane/EtOAc, 8:1) gave **14** as a pale yellow oil (2.28 g, 74%, >99:1 dr): ¹³[α]_D²⁰ + 38.1 (c 1.0, CHCl₃), lit.¹³ [α]_D²⁵ + 41.8 (c 1.5, CHCl₃); δ_H (400 MHz, CDCl₃) 1.39 (3H, d, J = 6.6 Hz, C(α)Me), 1.49 (9H, s, CMe₃), 1.68–1.75 (1H, m, C(S')H_A), 2.07–2.11 (1H, m, C(S')H_B), 2.38 (1H, dd, J = 14.2, 6.3 Hz, C(2)H_A), 2.45–2.51 (1H, m, C(6')H_A), 2.61 (1H, dd, J = 14.2, 7.2 Hz, C(2)H_B), 2.82–2.89 (1H, m, C(6')H_B), 3.73–3.76 (1H, m, C(2')H), 3.91 (1H, q, J = 6.6 Hz, C(α)H), 5.66 (1H, dt, J = 10.1, 3.8 Hz, C(3')H), 5.80–5.84 (1H, m, C(4')H), 7.21–7.33 (5H, m, Ph).

tert-Butyl (R,R,R)-2-Hydroxy-2-[N(1')-(α-methylbenzyl)-1',2',5',6'-tetrahydropyridin-2'-yl]ethanoate 15. Grubbs I catalyst (714 mg, 1.14 mmol) was added to a stirred solution of **13** (4.10 g, 11.4 mmol, >99:1 dr) in anhydrous, degassed CH₂Cl₂ (500 mL) at rt. The resultant mixture was stirred at 40 °C for 48 h and then concentrated in vacuo. The residue was dissolved in CH₂Cl₂ (180 mL). The resultant mixture was stirred at rt, and P(CH₂OH)₃²⁶ (14.2 g, 114 mmol) and Et₃N (3.18 mL, 22.8 mmol) were added sequentially. The resultant mixture was stirred at rt for 5 min. Then, excess silica gel (~10 g) was added, and stirring was continued for 12 h. The reaction mixture was then concentrated in vacuo. Purification via flash column chromatography (eluent isohexane/EtOAc, 4:1) gave **15** as a pale yellow oil (2.74 g, 76%, >99:1 dr): [α]_D²³ + 48.7 (c 1.0, CHCl₃); ν_{max} (film) 3500 (O—H), 2977 (C—H), 1727 (C=O), 1654 (C=C); δ_H (400 MHz, CDCl₃) 1.47 (3H, obsc d, C(α)Me), 1.49 (9H, s, CMe₃), 1.93–2.09 (2H, m, C(S')H₂), 2.36–2.42 (1H, m, C(6')H_A), 3.06 (1H, ddd, J = 12.0, 6.7, 5.0 Hz, C(6')H_B), 3.62 (1H, app d, J = 2.2 Hz, C(2')H), 4.08 (1H, q, J = 6.8 Hz, C(α)H), 4.43 (1H, d, J = 3.9 Hz, C(2)H), 5.41 (1H, ddt, J = 10.0, 3.4, 2.2 Hz, C(3')H), 5.98 (1H, dtd, J = 10.0, 3.9, 2.0 Hz, C(4')H), 7.21–7.33 (5H, m, Ph); δ_C (100 MHz, CDCl₃) 20.5 (C(α)Me), 23.9 (C(S')), 28.0 (CMe₃), 41.1 (C(6')), 58.0 (C(α)), 58.6 (C(2')), 71.0 (C(2)), 81.8 (CMe₃), 124.0 (C(3')), 127.2, 128.0, 128.2 (o,m,p-Ph), 129.4 (C(4')), 141.5 (i-Ph), 172.4 (C(1)); m/z (ESI⁺) 318 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₉H₂₇NNaO₃⁺ ([M + Na]⁺) requires 340.1883, found 340.1869.

Methyl (2'S,αR)-2-[N(1')-(α-Methylbenzyl)-1',2',5',6'-tetrahydropyridin-2'-yl]ethanoate 16. SOCl₂ (1.35 mL, 18.6 mmol) was added to MeOH (3.0 mL) at 0 °C, and the resultant mixture was stirred at rt for 1 min. A solution of **14** (800 mg, 2.65 mmol, >99:1 dr) in MeOH (3.0 mL) was then added, and the reaction mixture was stirred at rt for 16 h and then concentrated in vacuo. The residue was partitioned between saturated aq NaHCO₃ (10 mL) and CH₂Cl₂ (10 mL), and the aqueous layer was extracted with CH₂Cl₂ (2 × 10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent isohexane/EtOAc, 4:1) gave **16** as yellow oil (520 mg, 75%, >99:1 dr): ¹³[α]_D²⁰ + 99.0 (c 1.0, CHCl₃), lit.¹³ [α]_D¹⁶ + 42.1 (c 1.0, CHCl₃); δ_H (400 MHz, CDCl₃) 1.36 (3H, d, J = 6.6 Hz, C(α)Me), 1.65–1.72 (1H, m, C(S')H_A), 2.08–2.18 (1H, m, C(S')H_B), 2.49 (1H, dd, J = 14.4, 6.3 Hz, C(2)H_A), 2.49–2.55 (1H, m, C(6')H_A), 2.69 (1H, dd, J = 14.4, 7.8 Hz, C(2)H_B), 2.84 (1H, ddd, J = 13.6, 10.1, 4.5 Hz, C(6')H_B), 3.65 (3H, s, OMe), 3.83–3.87 (1H, m, C(2')H), 3.88 (1H, q, J = 6.6 Hz, C(α)H), 5.65–5.69 (1H, m, C(3')H), 5.84–5.88 (1H, m, C(4')H), 7.21–7.33 (5H, m, Ph).

Methyl (R,R,R)-2-Hydroxy-2-[N(1')-(α-methylbenzyl)-1',2',5',6'-tetrahydropyridin-2'-yl]ethanoate 17. SOCl₂ (1.28 mL, 17.6 mmol) was added to MeOH (3.0 mL) at 0 °C, and the

resultant mixture was stirred at rt for 1 min. A solution of **15** (800 mg, 2.52 mmol, >99:1 dr) in MeOH (3.0 mL) was added, and the reaction mixture was stirred at rt for 16 h and then concentrated in vacuo. The residue was partitioned between saturated aq NaHCO₃ (10 mL) and CH₂Cl₂ (10 mL), and the aqueous layer was extracted with CH₂Cl₂ (2 × 10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent isohexane/EtOAc, 4:1) gave **17** as yellow oil (560 mg, 81%, >99:1 dr): [α]_D²⁰ + 59.4 (c 1.0, CHCl₃); ν_{max} (ATR) 3505 (O—H), 1739 (C=O), 1655 (C=C); δ_H (400 MHz, CDCl₃) 1.47 (3H, d, J = 6.6 Hz, C(α)Me), 1.92–1.96 (1H, m, C(S')H_A), 2.01–2.07 (1H, m, C(S')H_B), 2.36–2.42 (1H, m, C(6')H_A), 2.99 (1H, dt, J = 11.9, 5.8 Hz, C(6')H_B), 3.69–3.70 (1H, m, C(2')H), 3.77 (3H, s, OMe), 4.04 (1H, q, J = 6.6 Hz, C(α)H), 4.54 (1H, d, J = 4.8 Hz, C(2)H), 5.41 (1H, dd, J = 10.1, 1.5 Hz, C(3')H), 5.98–6.00 (1H, m, C(4')H), 7.26–7.37 (5H, m, Ph); δ_C (100 MHz, CDCl₃) 20.5 (C(α)Me), 23.5 (C(S')), 41.2 (C(6')), 58.0 (C(α)), 58.3 (C(2')), 71.1 (C(2)), 123.9 (C(3')), 127.3, 128.0, 128.3 (o,m,p-Ph), 129.7 (C(4')), 141.5 (i-Ph), 173.5 (C(1)); m/z (ESI⁺) 276 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₆H₂₁NNaO₃⁺ ([M + Na]⁺) requires 298.1414, found 298.1410.

tert-Butyl (2'S,3'S,4'R,αR)-2-[N(1')-(α-Methylbenzyl)-3',4'-dihydropiperidin-2'-yl]ethanoate 19. Method A – Upjohn Oxidation. OsO₄ (13 mg, 49 μmol) was added to a stirred solution of **14** (150 mg, 0.49 mmol, >99:1 dr) in THF/H₂O (4:1, 1.2 mL) followed by a solution of NMO (233 mg, 1.99 mmol) in H₂O (0.1 mL), and the resultant mixture was stirred at rt for 12 h. Saturated aq Na₂SO₃ (1 mL) was then added, and the resultant mixture was left to stir at rt for 1 h. The reaction mixture was then extracted with EtOAc (3 × 3 mL), and the combined organic extracts were dried and concentrated in vacuo to give **19** (94:6 dr). Purification via flash column chromatography (eluent 30–40 °C petrol/EtOAc, 4:1) gave **19** as a yellow oil (114 mg, 68%, >99:1 dr): [α]_D²⁰ + 11.2 (c 0.5, CHCl₃); ν_{max} (film) 3418 (O—H), 1726 (C=O); δ_H (400 MHz, CDCl₃) 1.37 (9H, s, CMe₃), 1.39 (3H, d, J = 6.6 Hz, C(α)Me), 1.62–1.73 (1H, m, C(S')H_A), 1.83–1.88 (1H, m, C(S')H_B), 2.25 (1H, dd, J = 14.4, 9.7 Hz, C(2)H_A), 2.37–2.50 (2H, m, C(2)H_B, C(6')H_A), 2.79 (1H, d, J = 9.6 Hz, OH), 2.93 (1H, dt, J = 12.4, 2.1 Hz, C(6')H_B), 3.31–3.35 (1H, m, C(2')H), 3.61–3.66 (1H, m, C(3')H), 3.70–3.79 (2H, m, C(4')H, C(α)H), 7.22–7.38 (5H, m, Ph); δ_C (100 MHz, CDCl₃) 21.4 (C(α)Me), 28.0 (CMe₃), 29.7 (C(S')), 30.3 (C(2)), 40.4 (C(6')), 58.1 (C(2')), 59.6 (C(α)), 66.1 (C(4')), 70.4 (C(3')), 80.9 (CMe₃), 127.0, 127.3, 128.3 (o,m,p-Ph), 144.2 (i-Ph), 170.9 (C(1)); m/z (ESI⁺) 336 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₉H₃₀NO₄⁺ ([M + H]⁺) requires 336.2169, found 336.2156.

Method B – Donohoe Oxidation. OsO₄ (186 mg, 0.73 mmol) was added to a stirred solution of **14** (200 mg, 0.66 mmol, >99:1 dr) and TMEDA (140 μL, 0.93 mmol) in CH₂Cl₂ (5 mL) at –78 °C. The resultant mixture was stirred at –78 °C for 1 h, and then allowed to warm to rt over 15 min before being concentrated in vacuo to give **18** (>99:1 dr). The residue of **18** was dissolved in CH₂Cl₂ (6 mL); the resultant solution was stirred at rt, and P(CH₂OH)₃²⁶ (7.56 g, 59.5 mmol) and Et₃N (1.67 mL, 11.9 mmol) were added sequentially. After the mixture had been stirred at rt for 5 min, excess silica gel (~5 g) was added, and stirring of the reaction mixture was continued at rt for 48 h. The resultant suspension was then concentrated in vacuo. Purification via flash column chromatography (eluent 30–40 °C petrol/EtOAc, 1:1) gave **19** as a colorless oil (162 mg, 73% from **14**, >99:1 dr), which displayed characterization data consistent with those described above.

tert-Butyl (2'S,3'S,4'R)-(3',4'-Dihydropiperidin-2'-yl)-ethanoate 20. Pd(OH)₂/C (50% w/w of substrate, 52 mg) was added to a stirred solution of **19** (104 mg, 0.31 mmol, >99:1 dr) in degassed MeOH (3 mL) at rt. The resultant suspension was placed under H₂ (1 atm) and stirred vigorously at rt for 12 h. The reaction mixture was then filtered through a short plug of Celite (eluent MeOH) and concentrated in vacuo to give **20** as a yellow oil (72 mg, quant, >99:1 dr): [α]_D²⁰ – 4.0 (c 0.5, CHCl₃); ν_{max} (film) 3316 (O—H), 1718 (C=O); δ_H (400 MHz, CDCl₃) 1.46 (9H, s, CMe₃), 1.70–1.79 (1H, m, C(S')H_A), 1.85–1.91 (1H, m, C(S')H_B), 2.35 (1H, dd, J = 16.4, 8.1 Hz, C(2)H_A), 2.71–2.79 (2H, m, C(2)H_B, C(6')H_A),

2.99 (1H, td, $J = 12.1, 3.0$ Hz, C(6')H_B), 3.14 (1H, app dt, $J = 8.1, 4.5$ Hz, C(2')H), 3.35 (1H, dd, $J = 9.2, 3.9$ Hz, C(3')H), 4.04 (1H, app q, $J = 3.9$ Hz, C(4')H); δ_C (100 MHz, CDCl₃) 28.1 (CMe₃), 31.9 (C(2)), 38.8 (C(5')), 39.5 (C(6')), 53.3 (C(2')), 68.0 (C(4')), 73.2 (C(3')), 81.2 (CMe₃), 172.7 (C(1)); m/z (ESI⁺) 232 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₁H₂₂NO₄⁺ ([M + H]⁺) requires 232.1543, found 232.1551.

(2'S,3'S,4'R)-(3',4'-Dihydroxypiperidin-2'-yl)ethanoic Acid 21. A solution of **20** (40 mg, 0.17 mmol, >99:1 dr) in 1.0 M aq HCl (2 mL) was stirred at rt for 12 h and then concentrated in vacuo. Purification via ion exchange chromatography (Dowex 50WX8–200, eluent 1.0 M aq NH₄OH) gave **21** as a white solid (23 mg, 77%, >99:1 dr): mp 137–138 °C; $[\alpha]_D^{20} - 72.6$ (c 0.5, MeOH); ν_{\max} (film) 3284 (O—H), 1577 (zwitterionic β -amino acid); δ_H (500 MHz, D₂O) 1.88–1.95 (1H, m, C(5')H_A), 2.00–2.05 (1H, m, C(5')H_B), 2.49 (1H, dd, $J = 17.5, 8.9$ Hz, C(2)H_A), 2.73 (1H, dd, $J = 17.5, 3.8$ Hz, C(2)H_B), 3.22 (2H, app dd, $J = 8.7, 3.8$ Hz, C(6')H₂), 3.55 (1H, td, $J = 8.9, 3.8$ Hz, C(2')H), 3.72 (1H, dd, $J = 8.9, 2.5$ Hz, C(3')H), 4.1 (1H, app td, $J = 5.1, 2.5$ Hz, C(4')H); δ_C (125 MHz, D₂O) 27.0 (C(5')), 34.7 (C(2)), 38.1 (C(6')), 52.9 (C(2')), 65.3 (C(4')), 68.7 (C(3')), 177.5 (C(1)); m/z (FI⁺) 175 ([M]⁺, 100%); HRMS (FI⁺) C₇H₁₃NO₄⁺ ([M]⁺) requires 175.0839, found 175.0849.

tert-Butyl (2R,2'R,3'S,4'R,αR)-2-Hydroxy-2-[N(1')-(α-methylbenzyl)-3',4'-dihydroxypiperidin-2'-yl]ethanoate 22. Method A – Upjohn Oxidation. OsO₄ (48 mg, 0.19 mmol) was added to a stirred solution of **15** (600 mg, 1.89 mmol, >99:1 dr) in THF/H₂O (4:1, 7.2 mL) followed by a solution of NMO (886 mg, 7.56 mmol) in H₂O (0.3 mL), and the resultant mixture was stirred at rt for 12 h. Saturated aq Na₂SO₃ (5 mL) was then added, and the resultant mixture was left to stir at rt for 1 h. The reaction mixture was then extracted with EtOAc (3 × 10 mL), and the combined organic extracts were dried and concentrated in vacuo. Purification via flash column chromatography (eluent PhMe/PrOH, 4:1) gave **22** as a yellow oil (425 mg, 64%, >99:1 dr): $[\alpha]_D^{20} + 22.6$ (c 1.0, CHCl₃); ν_{\max} (film) 3307 (O—H), 1732 (C=O); δ_H (400 MHz, CDCl₃) 1.37 (9H, s, CMe₃), 1.47 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.71–1.78 (1H, m, C(5')H_A), 1.80–1.86 (1H, m, C(5')H_B), 2.82–2.87 (1H, m, C(6')H_A), 2.97–3.04 (1H, m, C(6')H_B), 3.28 (1H, t, $J = 2.8$ Hz, C(2')H), 3.63 (1H, br s, C(3')H), 4.04–4.12 (2H, m, C(4')H, C(α)H), 4.56 (1H, d, $J = 2.8$ Hz, C(2)H), 7.22–7.37 (5H, m, Ph); δ_C (100 MHz, CDCl₃) 21.4 (C(α)Me), 28.0 (CMe₃), 29.3 (C(5')), 41.5 (C(6')), 58.9 (C(4')), 62.9 (C(2')), 67.5 (C(α)), 69.1 (C(3')), 69.3 (C(2)), 83.1 (CMe₃), 127.1, 127.2, 128.5 (*o,m,p*-Ph), 143.8 (*i*-Ph), 173.6 (C(1)); m/z (ESI⁺) 352 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₉H₃₀NO₅⁺ ([M + H]⁺) requires 352.2118, found 352.2120.

Method B – Donohoe Oxidation. OsO₄ (132 mg, 0.52 mmol) was added to a stirred solution of **15** (150 mg, 0.47 mmol, >99:1 dr) and TMEDA (100 μL, 0.66 mmol) in CH₂Cl₂ (5 mL) at –78 °C. The reaction mixture was stirred at –78 °C for 1 h, then allowed to warm to rt over 15 min, and concentrated in vacuo. The residue was dissolved in CH₂Cl₂ (6 mL). P(CH₂OH)₃²⁶ (3.94 g, 29.1 mmol) and Et₃N (0.81 mL, 5.81 mmol) were added sequentially, and the resultant solution was stirred at rt for 5 min. Excess silica gel (~5 g) was then added, and stirring of the mixture was continued at rt for 48 h. The resultant suspension was then concentrated in vacuo. Purification via flash column chromatography (eluent PhMe/PrOH, 4:1) gave **22** as a colorless oil (89 mg, 87%, >99:1 dr), which displayed characterization data consistent with those described above: $[\alpha]_D^{20} + 23.0$ (c 1.0, CHCl₃).

tert-Butyl (2R,2'S,3'S,4'R,αR)-2-Hydroxy-2-[N(1')-(α-methylbenzyl)-3',4'-dihydroxy-3',4'-O-isopropylidene-piperidin-2'-yl]ethanoate 23. TsOH·H₂O (162 mg, 0.85 mmol) was added to a stirred solution of **22** (600 mg, 1.70 mmol) in DMP/acetone (13:1, 8 mL), and the resultant mixture was stirred at 45 °C for 48 h. Saturated aq NaHCO₃ (10 mL) was then added, and the reaction mixture was extracted with CH₂Cl₂ (3 × 10 mL). The combined organic extracts were washed with brine (20 mL), dried, and concentrated in vacuo. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave **23** as a yellow solid (493 mg, 74%, >99:1 dr): mp 82–83 °C; $[\alpha]_D^{20} + 13.0$ (c 1.0, CHCl₃); ν_{\max} (film) 3445 (O—H), 1731

(C=O); δ_H (400 MHz, CDCl₃) 1.27 (3H, s, MeCMe), 1.42 (3H, s, MeCMe), 1.47 (3H, d, $J = 6.8$ Hz, C(α)Me), 1.49 (9H, s, CMe₃), 1.71–1.78 (1H, m, C(5')H_A), 1.81–1.89 (1H, m, C(5')H_B), 2.56 (1H, ddd, $J = 12.1, 9.2, 3.0$ Hz, C(6')H_A), 2.75 (1H, ddd, $J = 12.1, 6.6, 3.6$ Hz, C(6')H_B), 3.50 (1H, m, C(2)H), 4.10 (1H, dd, $J = 6.0, 3.0$ Hz, C(2')H), 4.16 (1H, q, $J = 6.8$ Hz, C(α)H), 4.21 (1H, m, C(3')H), 4.27 (1H, app q, $J = 5.0$ Hz, C(4')H), 7.21–7.37 (5H, m, Ph); δ_C (100 MHz, CDCl₃) 19.6 (C(α)Me), 25.5, 27.4 (CMe₃), 27.7 (C(5')), 28.0 (CMe₃), 40.4 (C(6')), 59.7 (C(2')), 59.8 (C(α)), 71.7 (C(4')), 72.4 (C(2)), 72.7 (C(3')), 82.7 (CMe₃), 107.4 (CMe₂), 126.9, 127.9, 128.2 (*o,m,p*-Ph), 143.0 (*i*-Ph), 173.1 (C(1)); m/z (ESI⁺) 392 ([M + H]⁺, 100%); HRMS (ESI⁺) C₂₂H₃₃NNaO₅⁺ ([M + Na]⁺) requires 414.2251, found 414.2247.

(2R,2'S,3'S,4'R,αR)-2-[N(1')-(α-Methylbenzyl)-3',4'-dihydroxy-3',4'-O-isopropylidene-piperidin-2'-yl]ethane-1,2-diol 24. LiAlH₄ (1.0 M in THF, 2.6 mL, 2.55 mmol) was added dropwise to a stirred solution of **23** (400 mg, 1.02 mmol, >99:1 dr) in THF (8 mL) at –78 °C; the resultant mixture was allowed to warm to rt over 16 h. Aq NaOH (1.0 M, 1 mL) was then added, and the resultant suspension was heated at reflux for 1 h. The reaction mixture was then filtered through a short plug of Celite (eluent EtOAc) and concentrated in vacuo. Purification via flash column chromatography (eluent PhMe/acetone, 3:1) gave **24** as a colorless oil (220 mg, 67%, >99:1 dr): $[\alpha]_D^{20} + 39.5$ (c 1.0, CHCl₃); ν_{\max} (film) 3395 (O—H), 2932 (C—H); δ_H (500 MHz, CDCl₃) 1.33 (3H, s, MeCMe), 1.45 (3H, s, MeCMe), 1.50 (3H, d, $J = 6.9$ Hz, C(α)Me), 1.66–1.74 (1H, m, C(5')H_A), 1.78–1.81 (1H, m, C(5')H_B), 2.49–2.54 (1H, m, C(6')H_A), 2.58–2.61 (1H, m, C(6')H_B), 3.28 (1H, dd, $J = 7.1, 3.3$ Hz, C(2')H), 3.76–3.78 (2H, m, C(1)H₂), 3.88–3.92 (1H, m, C(2)H), 4.24 (1H, q, $J = 6.9$ Hz, C(α)H), 4.29 (1H, app q, $J = 5.3$ Hz, C(4')H), 4.44 (1H, dd, $J = 6.1, 3.3$ Hz, C(3')H), 7.24–7.35 (5H, m, Ph); δ_C (125 MHz, CDCl₃) 20.5 (C(α)Me), 25.4 (C(5')), 25.8, 27.7 (CMe₂), 40.7 (C(6')), 59.6 (C(2')), 60.1 (C(α)), 65.7 (C(1)), 69.7 (C(2)), 71.0 (C(4')), 72.7 (C(3')), 107.8 (CMe₂), 127.3 (*p*-Ph), 127.6, 128.5 (*o,m*-Ph), 142.5 (*i*-Ph); m/z (ESI⁺) 322 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₈H₂₇NNaO₄⁺ ([M + Na]⁺) requires 344.1832, found 344.1834.

(2R,3S,4R,αR)-N(1)-(α-Methylbenzyl)-3,4-dihydroxypiperidine-2-carboxylic Acid 26. NaIO₄ (166 mg, 0.77 mmol) was added to a solution of **24** (100 mg, 0.31 mmol, >99:1 dr) in EtOH/H₂O (5:1, 4.4 mL) at rt, and the resultant suspension was stirred at rt for 20 min. The reaction mixture was then filtered through a short plug of Celite (eluent EtOH) and concentrated in vacuo. The residue was dissolved in Et₂O (10 mL), and the resultant solution was filtered through a short plug of Celite (eluent Et₂O) and concentrated in vacuo. Cyclohexene (0.32 mL) was added to a solution of the residue in BuOH (4.8 mL) at rt. A solution of NaClO₂ (31 mg, 0.34 mmol) and KH₂PO₄ (47 mg, 0.34 mmol) in H₂O (0.8 mL) was then added dropwise at rt. The resultant mixture was stirred at rt for 1 h and then concentrated in vacuo. The residue was partitioned between EtOAc (2 mL) and H₂O (2 mL), and the aqueous layer was extracted with EtOAc (2 × 2 mL). The combined organic extracts were then dried and concentrated in vacuo to give **25**. A solution of residue **25** in 1.0 M aq HCl (0.5 mL) was stirred at 40 °C for 12 h. The reaction mixture was then allowed to cool to rt and concentrated in vacuo. Purification via ion exchange chromatography (Dowex 50WX8–200, eluent 1.0 M aq NH₄OH) gave **26** as an orange oil (21 mg, 26% from **24**, 60:40 dr). Data for mixture: ν_{\max} (ATR) 3345 (O—H), 1457 (zwitterionic α -amino acid); m/z (ESI⁺) 266 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₄H₁₉NNaO₄⁺ ([M + Na]⁺) requires 288.1206, found 288.1219. Data for major diastereoisomer: δ_H (500 MHz, D₂O) 1.62 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.79–1.87 (2H, m, C(5)H₂), 2.82–2.87 (1H, m, C(6)H_A), 3.05–3.10 (1H, m, C(6)H_B), 3.31–3.39 (1H, m, C(2)H), 3.87–3.90 (2H, m, C(3)H, C(4)H), 4.32 (1H, q, $J = 6.6$ Hz, C(α)H), 7.40–7.48 (5H, m, Ph); δ_C (125 MHz, D₂O) 18.3 (C(α)Me), 27.0 (C(5)), 43.0 (C(6)), 58.3 (C(α)), 65.6 (C(3)), 70.1 (C(2)), 70.4 (C(4)), 127.5, 129.3, 129.5 (*o,m,p*-Ph), 136.1 (*i*-Ph), 177.9 (CO₂H). Data for minor diastereoisomer: δ_H (500 MHz, D₂O) 1.61 (3H, d, $J = 6.9$ Hz, C(α)Me), 1.93–2.02 (2H, m, C(5)H₂), 2.88–2.93 (1H, m, C(6)H_A), 2.98–3.03 (1H, m, C(6)H_B), 3.15 (1H, d, $J =$

7.6 Hz, C(2)H), 3.96–3.99 (1H, m, C(3)H), 4.02 (1H, app d, $J = 3.5$ Hz, C(4)H), 4.47 (1H, q, $J = 6.9$ Hz, C(α)H), 7.40–7.48 (5H, m, Ph); δ_C (125 MHz, D₂O) 17.2 (C(α)Me), 30.3 (C(5)), 42.8 (C(6)), 58.2 (C(α)), 65.0 (C(2)), 70.2 (C(3)), 75.3 (C(4)), 128.3, 129.2, 129.3 (*o,m,p*-Ph), 136.1 (*i*-Ph), 179.9 (CO₂H).

(2R,2'S,3'S,4'R)-2-[N(1')-tert-Butoxycarbonyl-3',4'-dihydroxy-3',4'-O-isopropylidenepiperidin-2'-yl]ethane-1,2-diol 27. Pd(OH)₂/C (50% w/w of substrate, 40 mg) was added to a stirred solution of **24** (80 mg, 0.25 mmol, >99:1 dr) and Boc₂O (59 mg, 0.27 mmol) in degassed MeOH (2 mL) at rt. The resultant suspension was placed under H₂ (1 atm) and stirred vigorously at rt for 12 h. The reaction mixture was then filtered through a short plug of Celite (eluent MeOH) and concentrated in vacuo to give **27** as a colorless oil (37 mg, 48%, >99:1 dr): $[\alpha]_D^{20} + 25.2$ (c 1.0, CHCl₃); ν_{\max} (ATR) 3416 (O—H), 2979 (C—H), 1665 (C=O); δ_H (500 MHz, CDCl₃) 1.33 (3H, s, MeCMe), 1.45 (3H, s, MeCMe), 1.46 (9H, s, CMe₃), 1.72–1.75 (1H, m, C(S')H_A), 1.81–1.86 (1H, m, C(S')H_B), 3.07 (1H, br s, OH), 3.21–3.23 (1H, m, C(6')H_A), 3.36–3.42 (2H, m, C(2)H, C(6')H_B), 3.57–3.61 (2H, m, C(1)H₂), 4.04 (1H, dd, $J = 10.5, 1.8$ Hz, C(2')H), 4.29 (1H, br s, OH), 4.41–4.43 (1H, m, C(4')H), 4.81–4.82 (1H, m, C(3')H); δ_C (125 MHz, CDCl₃) 24.2, 26.4 (CMe₃), 28.3 (CMe₃), 36.8 (C(S')), 53.9 (C(6')), 62.0 (C(1)), 68.8 (C(2')), 71.7 (C(4')), 72.6 (C(2)), 77.2 (C(3')), 80.9 (CMe₃), 107.6 (CMe₂), 157.9 (NCO); m/z (ESI⁺) 340 ([M + Na]⁺, 100%); HRMS (ESI⁺) C₁₅H₂₇NNaO₆⁺ ([M + Na]⁺) requires 340.1731, found 340.1738.

(2R,3S,4R)-3,4-Dihydroxypiperidine-2-carboxylic Acid [(–)-3,4-Dihydroxypipicolic Acid] 28. NaIO₄ (55 mg, 0.23 mmol) was added to a solution of **27** (30 mg, 91 μ mol, >99:1 dr) in EtOH/H₂O (5:1, 1.3 mL) at rt, and the resultant suspension was stirred at rt for 20 min. The reaction mixture was then filtered through a short plug of Celite (eluent EtOH) and concentrated in vacuo. The residue was dissolved in Et₂O (10 mL), and the resultant solution was filtered through a short plug of Celite (eluent Et₂O) and concentrated in vacuo. Cyclohexene (0.10 mL) was added to a solution of the residue in ^tBuOH (1.4 mL) at rt. A solution of NaClO₂ (85 mg, 0.95 mmol) and KH₂PO₄ (128 mg, 0.95 mmol) in H₂O (0.9 mL) was then added dropwise at rt. The resultant mixture was stirred at rt for 18 h and then concentrated in vacuo. The residue was partitioned between EtOAc (2 mL) and H₂O (2 mL), and the aqueous layer was extracted with EtOAc (2 \times 2 mL). The combined organic extracts were then dried and concentrated in vacuo. A solution of the residue in 2.0 M aq HCl (0.5 mL) was heated at reflux for 12 h. The reaction mixture was then allowed to cool to rt and concentrated in vacuo. Purification via ion exchange chromatography (Dowex 50WX8–200, eluent 1.0 M aq NH₄OH) gave **28** as an orange solid (13 mg, 67%, >99:1 dr): mp 233–238 °C (dec); $[\alpha]_D^{20} - 6.1$ (c 1.0, H₂O); ν_{\max} (ATR) 3345 (O—H), 2948 (C—H), 1452 (zwitterionic α -amino acid); δ_H (700 MHz, D₂O) 1.83–1.87 (1H, m, C(S)H_A), 1.99 (1H, dtd, $J = 14.5, 7.4, 4.5$ Hz, C(S)H_B), 3.17–3.24 (2H, m, C(6)H₂), 3.81 (1H, d, $J = 7.0$ Hz, C(2)H), 3.95–3.97 (1H, m, C(4)H), 4.09 (1H, dd, $J = 7.0, 2.4$ Hz, C(3)H); δ_C (175 MHz, D₂O) 25.8 (C(5)), 38.9 (C(6)), 59.2 (C(2)), 65.4 (C(4)), 68.4 (C(3)), 172.4 (CO₂H); m/z (ESI⁺) 162 ([M + H]⁺, 100%); HRMS (ESI⁺) C₆H₁₁NNaO₄⁺ ([M + Na]⁺) requires 184.0580, found 184.0583.

(2S,3S,4R, α R)-N(1)-(α -Methylbenzyl)-2-hydroxymethyl-3,4-dihydroxy-3,4-O-isopropylidenepiperidine 29. NaIO₄ (219 mg, 1.03 mmol) was added to a stirred solution of **24** (110 mg, 0.34 mmol, >99:1 dr) in EtOH/H₂O (5:1, 3.9 mL) at rt, and the resultant suspension was stirred at rt for 20 min. The reaction mixture was then filtered through a short plug of Celite (eluent EtOH), and the filtrate was concentrated in vacuo to half of its original volume. The residue was cooled to 0 °C, and NaBH₄ (30 mg, 0.79 mmol) was added. The resultant mixture was allowed to warm to rt and stirred at rt for 12 h before saturated aq NH₄Cl (0.5 mL) was added. The reaction mixture was then filtered through Celite (eluent CHCl₃/MeOH, 3:1) and concentrated in vacuo. Purification via flash column chromatography (eluent PhMe/acetone, 2:3) gave **29** as a yellow oil (62 mg, 62%, >99:1 dr): $[\alpha]_D^{20} + 48.3$ (c 1.0, CHCl₃); ν_{\max} (film) 3442 (O—H), 2982 (C—H); δ_H (400 MHz, CDCl₃) 1.29 (3H, s, MeCMe), 1.42 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.44 (3H, s, MeCMe), 1.55–1.63 (1H,

m, C(S)H_A), 1.77 (1H, dddd, $J = 14.2, 8.2, 6.0, 3.4$ Hz, C(S)H_B), 2.43–2.49 (1H, m, C(6)H_A), 2.52–2.58 (1H, m, C(6)H_B), 3.34–3.41 (2H, m, C(2)CH_AH_B, C(2)H), 3.62–3.68 (1H, m, C(2)CH_AH_B), 3.95–3.97 (1H, m, C(3)H), 4.14–4.21 (2H, m, C(α)H, C(4)H), 7.20–7.32 (5H, m, Ph); δ_C (100 MHz, CDCl₃) 20.7 (C(α)Me), 25.5 (C(5)), 25.6, 27.9 (CMe₂), 39.7 (C(6)), 56.3 (C(2)), 59.2 (C(α)), 59.9 (C(2)CH₂), 71.3 (C(4)), 73.7 (C(3)), 107.8 (CMe₂), 127.1 (*p*-Ph), 127.4, 128.3 (*o,m*-Ph), 143.4 (*i*-Ph); m/z (ESI⁺) 292 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₇H₂₆NO₃⁺ ([M + H]⁺) requires 292.1907, found 292.1897.

(2S,3S,4R)-2-Hydroxymethyl-3,4-dihydroxypiperidine [(–)-3-epi-Fagomine] 31. Step 1. Pd(OH)₂/C (50% w/w of substrate, 21 mg) was added to a stirred solution of **29** (42 mg, 0.15 mmol, >99:1 dr) in MeOH (0.5 mL). The resultant suspension was placed under H₂ (1 atm) and stirred vigorously at rt for 12 h. The reaction mixture was then filtered through a short plug of Celite (eluent MeOH) and concentrated in vacuo to give **30** as a yellow oil (28 mg, quant, >99:1 dr): δ_H (400 MHz, CDCl₃) 1.33 (3H, s, MeCMe), 1.47 (3H, s, MeCMe), 1.97–2.02 (1H, m, C(S)H_A), 2.08–2.12 (1H, m, C(S)H_B), 2.71–2.74 (1H, m, C(2)H), 2.84 (1H, td, $J = 12.3, 3.3$ Hz, C(6)H_A), 2.93–2.98 (1H, m, C(6)H_B), 3.56 (1H, dd, $J = 11.1, 7.2$ Hz, C(2)CH_AH_B), 3.81 (1H, dd, $J = 9.0, 4.9$ Hz, C(3)H), 3.87 (1H, dd, $J = 11.1, 3.3$ Hz, C(2)CH_AH_B), 4.11 (2H, br s, NH, OH), 4.28–4.31 (1H, m, C(4)H); δ_C (100 MHz, CDCl₃) 26.2 (MeCMe), 26.9 (C(5)), 28.3 (MeCMe), 40.2 (C(6)), 59.5 (C(2)), 62.4 (C(2)CH₂), 71.7 (C(4)), 72.7 (C(3)), 108.7 (CMe₂).

Step 2. A solution of **30** (20 mg, 0.11 mmol, >99:1 dr) in 1.0 M aq HCl (0.5 mL) was stirred at rt for 12 h and then concentrated in vacuo. Purification via ion exchange chromatography (Dowex 50WX8–200, eluent 1.0 M aq NH₄OH) gave **31** as a white solid (13 mg, 80%, >99:1 dr): ^{20e,21} mp 141–145 °C, lit.^{20e} mp 220–222 °C; $[\alpha]_D^{20} - 72.2$ (c 1.0, H₂O), lit.^{20e} for *ent*-**31** $[\alpha]_D^{26} + 74.4$ (c 0.95, H₂O), lit.²¹ for *ent*-**31** $[\alpha]_D + 69$ (c 0.5, H₂O); δ_H (500 MHz, D₂O) 1.65–1.71 (1H, m, C(S)H_A), 1.77–1.82 (1H, m, C(S)H_B), 2.73–2.83 (2H, m, C(6)H₂), 2.85 (1H, ddd, $J = 10.1, 6.6, 3.2$ Hz, C(2)H), 3.44 (1H, dd, $J = 10.1, 2.8$ Hz, C(3)H), 3.58 (1H, dd, $J = 11.7, 6.6$ Hz, C(2)CH_AH_B), 3.77 (1H, dd, $J = 11.7, 3.2$ Hz, C(2)H_AH_B), 4.03 (1H, q, $J = 2.8$ Hz, C(4)H).

(2R,2'R,3'S,4'R, α R)-2-Hydroxy-2-[N(1')-(α -methylbenzyl)-3',4'-dihydroxypiperidin-2'-yl]ethanoic Acid 33. A solution of **22** (60 mg, 0.17 mmol, >99:1 dr) in 1.0 M aq HCl (1.5 mL) was stirred at rt for 12 h and then concentrated in vacuo. Purification via ion exchange chromatography (Dowex 50WX8–200, eluent 1.0 M aq NH₄OH) gave **33** as a colorless oil (30 mg, 60%, >99:1 dr): $[\alpha]_D^{20} - 5.8$ (c 0.5, H₂O); ν_{\max} (ATR) 3351 (O—H), 1611 (C=O); δ_H (500 MHz, D₂O), 1.65 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.76–1.78 (1H, m, C(S')H_A), 2.06 (1H, app dtd, $J = 14.0, 10.4, 3.8$ Hz, C(S')H_B), 2.93–2.95 (1H, m, C(6')H_A), 3.30–3.31 (1H, m, C(6')H_B), 3.76–3.77 (1H, m, C(2')H), 4.08–4.19 (2H, m, C(3')H, C(4')H), 4.48 (1H, d, $J = 6.9$ Hz, C(2)H), 4.92–4.93 (1H, m, C(α)H), 7.43–7.50 (5H, m, Ph); δ_C (125 MHz, D₂O) 18.4 (C(α)Me), 23.3 (C(S')), 42.9 (C(6')), 61.8 (C(α)), 63.0 (C(2')), 64.7 (C(4')), 66.9 (C(3')), 67.0 (C(2)), 127.9, 129.5, 129.9 (*o,m,p*-Ph), 136.7 (*i*-Ph), 177.6 (C(1)); m/z (ESI⁺) 296 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₃H₂₁NNaO₅⁺ ([M + Na]⁺) requires 318.1312, found 318.1307.

tert-Butyl (2R,2'R,3'S,4'R)-2-Hydroxy-2-(3',4'-dihydroxypiperidin-2'-yl)ethanoate 34. Pd(OH)₂/C (50% w/w of substrate, 35 mg) was added to a stirred solution of **22** (70 mg, 0.20 mmol, >99:1 dr) in degassed MeOH (1.5 mL). The resultant suspension was placed under H₂ (1 atm) and stirred vigorously at rt for 12 h. The reaction mixture was then filtered through a short plug of Celite (eluent MeOH) and concentrated in vacuo to give **34** as a colorless oil (49 mg, quant, >99:1 dr): $[\alpha]_D^{20} - 18.2$ (c 0.5, MeOH); ν_{\max} (ATR) 3346 (O—H, N—H), 2978 (C—H), 1728 (C=O); δ_H (500 MHz, MeOH-*d*₄) 1.59 (9H, s, CMe₃), 1.83–1.89 (1H, m, C(S')H_A), 1.94–1.97 (1H, m, C(S')H_B), 3.02–3.09 (1H, m, C(6')H_A), 3.25 (1H, app td, $J = 12.8, 3.2$ Hz, C(6')H_B), 3.70 (1H, dd, $J = 10.2, 1.1$ Hz, C(2')H), 3.85 (1H, dd, $J = 10.2, 2.5$ Hz, C(3')H), 4.02–4.04 (1H, m, C(4')H), 4.26–4.27 (1H, m, C(2)H); δ_C (125 MHz, MeOH-*d*₄) 28.4

(CMe₃), 29.9 (C(5')), 40.2 (C(6')), 58.4 (C(2')), 67.6 (C(3')), 67.9 (C(4')), 70.4 (C(2)), 83.6 (CMe₃), 171.8 (C(1)); *m/z* (ESI⁺) 248 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₁H₂₂NO₃⁺ ([M + H]⁺) requires 248.1492, found 248.1496.

(2*R*,2'*R*,3'*S*,4'*R*)-2-Hydroxy-2-(3',4'-dihydropiperidin-2'-yl)ethanoic Acid 35. A solution of **34** (30 mg, 0.12 mmol, >99:1 dr) in 1.0 M aq HCl (1.5 mL) was stirred at rt for 12 h and then concentrated in vacuo. Purification via ion exchange chromatography (Dowex 50WX8–200, eluent 1.0 M aq NH₄OH) gave **35** as a white solid (19 mg, 80%, >99:1 dr): mp 150–145 °C; [α]_D²⁰ – 46.4 (c 0.5, H₂O); ν_{max} (ATR) 3317 (O—H), 2944 (C—H), 1415 (zwitterionic β-amino acid); δ_H (500 MHz, D₂O) 1.87–1.94 (1H, m, C(5')H_A), 1.96–2.02 (1H, m, C(5')H_B), 3.21–3.24 (2H, m, C(6')H₂), 3.67 (1H, dd, *J* = 10.1, 2.8 Hz, C(2')H), 3.95 (1H, dd, *J* = 10.1, 2.8 Hz, C(3')H), 4.09–4.11 (1H, m, C(4')H), 4.19 (1H, d, *J* = 2.8 Hz, C(2)H); δ_C (125 MHz, D₂O) 26.9 (C(5')), 38.6 (C(6')), 57.2 (C(2')), 65.9 (C(4')), 66.0 (C(3')), 69.6 (C(2)), 176.4 (C(1)); *m/z* (ESI⁺) 192 ([M + H]⁺, 100%); HRMS (ESI⁺) C₇H₁₄NO₃⁺ ([M + H]⁺) requires 192.0866, found 192.0869.

(3*S*,4*R*,5*R*,α*R*)-5-Hydroxy-3,7-*N*-(α-methylbenzyl)imino-4-heptanolactone 36. *Method A (from 14).* HBF₄ (48% aq, 217 μL, 1.66 mmol) was added to a stirred solution of **14** (100 mg, 0.33 mmol, >99:1 dr) in CH₂Cl₂ (1 mL) at rt, and the resultant mixture was stirred at rt for 5 min. *m*-CPBA (75%, 305 mg, 1.33 mmol) was then added, and the resultant mixture was stirred at rt for 48 h. A mixture of CHCl₃/PrOH (3:1, 10 mL) was then added, and the organic layer was washed with saturated aq Na₂SO₃ (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was then washed with saturated aq NaHCO₃ (5 mL), and the combined aqueous washings were extracted with CHCl₃/PrOH (3:1, 3 × 10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave **36** as a yellow oil (36 mg, 41%, >99:1 dr): [α]_D²⁰ + 39.9 (c 1.0, CHCl₃); ν_{max} (ATR) 3407 (O—H), 1773 (C=O); δ_H (400 MHz, CDCl₃) 1.41 (3H, d, *J* = 6.7 Hz, C(α)Me), 1.69 (1H, app dtd, *J* = 13.6, 9.7, 4.8 Hz, C(6)H_A), 1.99 (1H, app dtd, *J* = 13.6, 8.3, 5.0 Hz, C(6)H_B), 2.25 (1H, dd, *J* = 17.0, 7.4 Hz, C(2)H_A), 2.47–2.53 (1H, m, C(7)H_A), 2.58 (1H, dd, *J* = 17.0, 9.6 Hz, C(2)H_B), 2.96 (1H, app dd, *J* = 12.1, 4.8 Hz, C(7)H_B), 3.61 (1H, q, *J* = 6.7 Hz, C(α)H), 3.69 (1H, app dt, *J* = 9.6, 7.4 Hz, C(3)H), 3.77 (1H, ddd, *J* = 9.7, 7.0, 4.8 Hz, C(5)H), 4.25 (1H, app t, *J* = 7.0 Hz, C(4)H), 7.16–7.37 (5H, m, *Ph*); δ_C (100 MHz, CDCl₃) 20.8 (C(α)Me), 27.7 (C(2)), 29.6 (C(6)), 39.7 (C(7)), 56.0 (C(3)), 61.2 (C(α)), 69.4 (C(5)), 82.0 (C(4)), 127.1, 127.5, 128.7 (*o,m,p-Ph*), 142.7 (*i-Ph*), 175.3 (C(1)); *m/z* (ESI⁺) 262 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₅H₁₉NNaO₃⁺ ([M + Na]⁺) requires 284.1257, found 284.1249.

Method B (from 16). HBF₄ (48% aq, 251 μL, 1.93 mmol) was added to a stirred solution of **16** (100 mg, 0.39 mmol, >99:1 dr) in CH₂Cl₂ (1 mL) at rt, and the resultant solution was stirred at rt for 5 min. *m*-CPBA (75%, 355 mg, 1.54 mmol) was then added, and the resultant mixture was stirred at rt for 48 h. A mixture of CHCl₃/PrOH (3:1, 5 mL) was then added, and the organic layer was washed with saturated aq Na₂SO₃ (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was then washed with saturated aq NaHCO₃ (5 mL), and the combined aqueous layers were extracted with CHCl₃/PrOH (3:1, 3 × 10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave lactone **36** as a yellow oil (32 mg, 32%, >99:1 dr), which displayed characterization data consistent with those described above.

Method C (from 37). HBF₄ (48% aq, 68 μL, 0.52 mmol) was added to a stirred solution of **37** (35 mg, 0.10 mmol, >99:1 dr) in CH₂Cl₂ (0.5 mL) at rt, and the resultant mixture was stirred at rt for 48 h. A mixture of CHCl₃/PrOH (3:1, 5 mL) was then added, and the organic layer was washed with saturated aq NaHCO₃ (1 mL), dried, and concentrated in vacuo. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave **36** as a yellow oil (11 mg, 41%, >99:1 dr), which displayed characterization data consistent with those described above.

Method D (from 41). HBF₄ (48% aq, 72 μL, 0.52 mmol) was added to a stirred solution of **41** (35 mg, 0.11 mmol, >99:1 dr) in CH₂Cl₂ (0.5 mL) at rt, and the resultant mixture was stirred at rt for 48 h. A mixture of CHCl₃/PrOH (3:1, 2 mL) was then added, and the organic layer was washed with saturated aq NaHCO₃ (1 mL), dried, and concentrated in vacuo. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave **36** as a yellow oil (14 mg, 48%, >99:1 dr), which displayed characterization data consistent with those described above.

Method E (from 44). HBF₄ (48% aq, 47 μL, 0.36 mmol) was added to a stirred solution of **44** (20 mg, 0.07 mmol, >99:1 dr) in CH₂Cl₂ (0.2 mL) at rt, and the resultant solution was stirred at rt for 48 h. A mixture of CHCl₃/PrOH (3:1, 2 mL) was then added, and the organic layer was washed with saturated aq NaHCO₃ (1 mL), dried, and concentrated in vacuo. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave **36** as a yellow oil (9 mg, 50%, >99:1 dr), which displayed characterization data consistent with those described above.

tert-Butyl (2'*S*,3'*R*,4'*R*,α*R*)-2-[*N*(1')-(α-Methylbenzyl)-3',4'-dihydropiperidin-2'-yl]ethanoate 37 and tert-Butyl (2'*S*,3'*S*,4'*S*,α*R*)-2-[*N*(1')-(α-Methylbenzyl)-3',4'-dihydropiperidin-2'-yl]ethanoate 38. CCl₃CO₂H (542 mg, 3.32 mmol) was added to a stirred solution of **14** (200 mg, 0.66 mmol, >99:1 dr) in CH₂Cl₂ (2 mL) at rt, and the resultant mixture was stirred at rt for 5 min. *m*-CPBA (75%, 611 mg, 2.65 mmol) was then added, and the resultant mixture was stirred at rt for 48 h. A mixture of CHCl₃/PrOH (3:1, 5 mL) was then added, and the organic layer was washed with saturated aq Na₂SO₃ (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was washed with saturated aq NaHCO₃ (5 mL), and the combined aqueous layers were extracted with CHCl₃/PrOH (3:1, 3 × 10 mL). The combined organic extracts were then dried and concentrated in vacuo to give a 34:56:10 mixture of **36**, **37**, and **38**, respectively. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave **36** as a colorless oil (21 mg, 12%, >99:1 dr). Further elution gave **37** as a yellow solid (33 mg, 15%, >99:1 dr): mp 96–97 °C; [α]_D²⁰ – 15.3 (c 1.0, CHCl₃); ν_{max} (ATR) 3397 (O—H), 1726 (C=O); δ_H (400 MHz, CDCl₃) 1.35 (3H, d, *J* = 6.6 Hz, C(α)Me), 1.41 (9H, s, CMe₃), 1.57–1.68 (1H, m, C(5')H_A), 1.84–1.89 (1H, m, C(5')H_B), 2.42–2.53 (3H, m, C(2)H₂, C(6')H_A), 2.83–2.88 (1H, m, C(6')H_B), 3.54–3.68 (3H, m, C(2')H, C(3')H, C(4')H), 3.97 (1H, q, *J* = 6.6 Hz, C(α)H), 7.20–7.30 (5H, m, *Ph*); δ_C (100 MHz, CDCl₃) 22.1 (C(α)Me), 28.0 (CMe₃), 30.2 (C(2)), 31.1 (C(5')), 41.0 (C(6')), 56.2 (C(2')), 59.4 (C(α)), 70.2 (C(4')), 74.2 (C(3')), 80.9 (CMe₃), 127.0, 127.9, 128.4 (*o,m,p-Ph*), 145.4 (*i-Ph*), 173.4 (C(1)); *m/z* (ESI⁺) 336 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₉H₃₀NO₄⁺ ([M + H]⁺) requires 336.2169, found 336.2167. Further elution gave **38** as a colorless oil (16 mg, 7%, >99:1 dr): [α]_D²⁰ + 13.7 (c 0.5, CHCl₃); ν_{max} (ATR) 3345 (O—H), 1725 (C=O); δ_H (500 MHz, CDCl₃) 1.45 (9H, s, CMe₃), 1.57 (3H, d, *J* = 6.9 Hz, C(α)Me), 1.67–1.74 (1H, m, C(5')H_A), 2.02–2.06 (1H, m, C(5')H_B), 2.21–2.26 (1H, m, C(6')H_A), 2.86–2.88 (1H, m, C(2')H), 2.95 (2H, app d, *J* = 5.7 Hz, C(2)H₂), 3.04–3.08 (1H, m, C(6')H_B), 3.44–3.48 (1H, m, C(4')H), 3.65 (1H, t, *J* = 7.1 Hz, C(3')H), 4.38 (1H, q, *J* = 6.9 Hz, C(α)H), 4.80 (2H, br s, 2 × OH), 7.22–7.38 (5H, m, *Ph*); δ_C (125 MHz, CDCl₃) 19.6 (C(α)Me), 28.1 (CMe₃), 30.4 (C(5')), 34.2 (C(2)), 41.8 (C(6')), 56.8 (C(α)), 59.9 (C(2')), 72.0 (C(4')), 74.9 (C(3')), 81.1 (CMe₃), 127.1, 127.9, 128.9 (*o,m,p-Ph*), 140.5 (*i-Ph*), 172.3 (C(1)); *m/z* (ESI⁺) 336 ([M + H]⁺, 100%); HRMS (ESI⁺) C₁₉H₃₀NO₄⁺ ([M + H]⁺) requires 336.2169, found 336.2169.

(3*S*,4*S*,5*S*,α*R*)-4-Hydroxy-3,7-*N*-(α-methylbenzyl)imino-5-heptanolactone 39 and (3*S*,4*S*,5*S*,α*R*)-5-Hydroxy-3,7-*N*-(α-methylbenzyl)imino-4-heptanolactone 40. HBF₄ (48% aq, 48 μL, 0.45 mmol) was added to a stirred solution of **38** (30 mg, 0.09 mmol, >99:1 dr) in CH₂Cl₂ (0.4 mL) at rt, and the resultant mixture was stirred at rt for 48 h. CHCl₃/PrOH (3:1, 1 mL) was then added, and the organic layer was washed with saturated aq NaHCO₃ (1 mL), dried, and concentrated in vacuo to give a 70:30 mixture of **39** and **40**, respectively. Purification via flash column chromatography (eluent CHCl₃/PrOH, 95:5) gave **39** as a white solid (16 mg, 70%, >99:1 dr):

mp 97–98 °C; $[\alpha]_{\text{D}}^{20} + 59.3$ (c 1.0, CHCl_3); ν_{max} (ATR) 3505 (O—H), 1739 (C=O); δ_{H} (500 MHz, CDCl_3) 1.34 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.99 (1H, app d, $J = 14.8$ Hz, C(6) H_{A}), 2.25–2.34 (2H, m, C(6) H_{B} , C(7) H_{A}), 2.52 (1H, app td, $J = 12.8, 3.2$ Hz, C(2) H_{A}), 2.84 (1H, d, $J = 19.2$ Hz, C(7) H_{B}), 3.08–3.13 (2H, m, C(2) H_{B} , C(4) H), 3.26 (1H, d, $J = 9.8$ Hz, OH), 3.63 (1H, q, $J = 6.6$ Hz, C(α)H), 3.81–3.86 (1H, m, C(3)H), 4.50 (1H, d, $J = 2.2$ Hz, C(5)H), 7.24–7.51 (5H, m, Ph); δ_{C} (125 MHz, CDCl_3) 21.4 (C(α)Me), 26.4 (C(6)), 27.6 (C(7)), 38.7 (C(2)), 52.0 (C(4)), 61.1 (C(α)), 63.6 (C(3)), 74.7 (C(5)), 127.0, 127.8, 129.0 (*o,m,p*-Ph), 143.2 (*i*-Ph), 169.6 (C(1)); m/z (ESI⁺) 262 ([M + H]⁺, 100%); HRMS (ESI⁺) $\text{C}_{15}\text{H}_{20}\text{NO}_3^+$ ([M + H]⁺) requires 262.1438, found 262.1440. Further elution gave **40** as a colorless oil (6 mg, 29%, >99:1 dr): $[\alpha]_{\text{D}}^{20} + 79.8$ (c 0.5, CHCl_3); ν_{max} (ATR) 3407 (O—H), 1785 (C=O); δ_{H} (500 MHz, CDCl_3) 1.48 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.64–1.71 (1H, m, C(6) H_{A}), 2.06–2.21 (3H, m, C(6) H_{B} , C(7) H_{A} , OH), 2.34–2.39 (1H, m, C(3)H), 2.45–2.51 (1H, m, C(2) H_{A}), 2.75 (1H, dd, $J = 15.4, 5.7$ Hz, C(2) H_{B}), 3.06 (1H, app d, $J = 10.1$ Hz, C(7) H_{B}), 3.66–3.71 (1H, m, C(5)H), 3.80–3.87 (2H, m, C(4)H, C(α)H), 7.21–7.40 (5H, m, Ph); δ_{C} (125 MHz, CDCl_3) 17.0 (C(α)Me), 31.9 (C(6)), 36.2 (C(2)), 46.2 (C(7)), 60.1 (C(α)), 61.3 (C(3)), 70.1 (C(5)), 87.2 (C(4)), 127.6, 128.0, 128.2 (*o,m,p*-Ph), 138.6 (*i*-Ph), 173.7 (C(1)); m/z (ESI⁺) 262 ([M + H]⁺, 100%); HRMS (ESI⁺) $\text{C}_{15}\text{H}_{19}\text{NNO}_3^+$ ([M + Na]⁺) requires 284.1257, found 284.1260.

tert-Butyl (2'S,3'R,4'S, α R)-2-[N(1')-(α -Methylbenzyl)-3',4'-epoxypiperidin-2'-yl]ethanoate **41.** (CF_3CO)₂O (0.18 mL, 1.33 mmol) was added to a stirred solution of UHP (468 mg, 4.97 mmol) and CH_2Cl_2 (1.5 mL) at 0 °C, and the resultant mixture was stirred at 0 °C for 30 min. A solution of **14** (100 mg, 0.33 mmol, >99:1 dr) and $\text{CF}_3\text{CO}_2\text{H}$ (62 μL , 0.83 mmol) in CH_2Cl_2 (1.5 mL) was added, and the resultant mixture was stirred at rt for 16 h. Saturated aq Na_2SO_3 (2 mL) was then added until starch iodide paper indicated no remaining oxidant. CH_2Cl_2 (5 mL) was then added, and the organic layer was washed with 2.0 M aq NaOH (2 \times 5 mL). The combined aqueous layers were extracted with CH_2Cl_2 (2 \times 10 mL); then, the combined organic extracts were dried and concentrated in vacuo to give a 29:26:45 mixture of **36**, **41**, and **37**, respectively. Purification via flash column chromatography (eluent $\text{CHCl}_3/\text{PrOH}$, 95:5) gave **37** as a yellow oil (20 mg, 18%, >99:1 dr). Further elution gave **36** as a yellow oil (6 mg, 7%, >99:1 dr). Then, further elution gave **41** as a colorless oil (15 mg, 14%, >99:1 dr): $[\alpha]_{\text{D}}^{20} + 2.8$ (c 0.5, CHCl_3); ν_{max} (ATR) 2979 (C—H), 1718 (C=O); δ_{H} (500 MHz, CDCl_3) 1.36 (3H, d, $J = 6.5$ Hz, C(α)Me), 1.48 (9H, s, CMe_3), 1.55–1.58 (1H, m, C(5') H_{A}), 1.87–1.94 (1H, m, C(5') H_{B}), 2.30–2.34 (1H, m, C(6') H_{A}), 2.51–2.65 (3H, m, C(2) H_2 , C(6') H_{B}), 3.26 (1H, app t, $J = 4.4$ Hz, C(3')H), 3.33–3.34 (1H, m, C(4')H), 3.77–3.84 (2H, m, C(2')H, C(α)H), 7.21–7.27 (5H, m, Ph); δ_{C} (125 MHz, CDCl_3) 20.8 (C(5')), 22.5 (C(α)Me), 28.1 (CMe₃), 35.5 (C(6')), 36.3 (C(2')), 49.6 (C(2')), 51.9 (C(4')), 52.5 (C(3')), 58.2 (C(α)), 80.2 (CMe₃), 126.9 (*p*-Ph), 127.1, 128.3 (*o,m*-Ph), 144.8 (*i*-Ph), 171.5 (C(1)); m/z (ESI⁺) 318 ([M + H]⁺, 100%); HRMS (ESI⁺) $\text{C}_{19}\text{H}_{28}\text{NO}_3^+$ ([M + H]⁺) requires 318.2064, found 318.2063.

(3S,4R,5R, α R)-5-(*p*-Toluenesulfonyloxy)-3,7-N-(α -methylbenzyl)imino-4-heptanolactone **42.** Method A (from **14**). TsOH·H₂O (315 mg, 1.66 mmol) was added to a stirred solution of **14** (100 mg, 0.33 mmol) in CH_2Cl_2 (1 mL) at rt, and the resultant mixture was stirred at rt for 5 min. *m*-CPBA (75%, 305 mg, 1.33 mmol) was then added, and the reaction mixture was stirred at rt for 48 h. A mixture of $\text{CHCl}_3/\text{PrOH}$ (3:1, 2 mL) was then added, and the organic layer was washed with saturated aq Na_2SO_3 (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was washed with saturated aq NaHCO_3 (5 mL), and the combined aqueous layers were extracted with $\text{CHCl}_3/\text{PrOH}$ (3:1, 3 \times 10 mL). The combined organic extracts were then dried and concentrated in vacuo to give a 56:44 mixture of **36** and **42**, respectively. Purification via flash column chromatography (eluent $\text{CHCl}_3/\text{PrOH}$, 95:5) gave **42** as a yellow oil (51 mg, 37%, >99:1 dr): $[\alpha]_{\text{D}}^{20} + 8.3$ (c 1.0, CHCl_3); ν_{max} (ATR) 1785 (C=O); δ_{H} (400 MHz, CDCl_3) 1.39 (3H, d, $J = 6.8$ Hz, C(α)Me), 1.76–1.85 (1H, m, C(6) H_{A}), 2.11–2.19 (1H, m, C(6) H_{B}), 2.30 (1H, dd, $J = 16.9, 6.4$ Hz, C(2) H_{A}), 2.45 (3H, s, ArMe),

2.55–2.64 (2H, m, C(2) H_{B} , C(7) H_{A}), 2.68–2.72 (1H, m, C(7) H_{B}), 3.52 (1H, app q, $J = 6.4$ Hz, C(3)H), 3.70 (1H, q, $J = 6.8$ Hz, C(α)H), 4.24 (1H, app t, $J = 6.0$ Hz, C(4)H), 4.51 (1H, ddd, $J = 8.2, 6.0, 4.4$ Hz, C(5)H), 7.20–7.77 (9H, m, Ph, Ar); δ_{C} (100 MHz, CDCl_3) 20.1 (C(α)Me), 21.7 (ArMe), 28.8 (C(6)), 30.0 (C(2)), 38.8 (C(7)), 56.1 (C(3)), 60.0 (C(α)), 77.5 (C(5)), 77.8 (C(4)), 127.4, 127.7, 127.9, 128.6, 129.8 (Ar, *o,m,p*-Ph), 133.2, 140.9 (Ar, *i*-Ph), 145.1 (CMe), 174.0 (C(1)); m/z (ESI⁺) 438 ([M + Na]⁺, 100%); HRMS (ESI⁺) $\text{C}_{22}\text{H}_{25}\text{NNO}_5\text{S}^+$ ([M + Na]⁺) requires 438.1346, found 438.1344. Further elution gave **36** as yellow oil (20 mg, 23%, >99:1 dr).

Method B (from **36).** TsCl (82 mg, 0.43 mmol) was added to a stirred solution of **36** (70 mg, 0.27 mmol, >99:1 dr) and pyridine (43 μL , 0.54 mmol) in CH_2Cl_2 (5 mL) at rt, and the resultant mixture was stirred at rt for 12 h. The reaction mixture was then washed with saturated aq CuSO_4 (5 mL). The aqueous layer was extracted with CH_2Cl_2 (3 \times 5 mL), and the combined organic extracts were washed with saturated aq NaHCO_3 (15 mL), dried, and concentrated in vacuo. Purification via flash column chromatography (eluent $\text{CHCl}_3/\text{PrOH}$, 95:5) gave **42** as a yellow oil (54 mg, 49%, >99:1 dr), which displayed characterization data consistent with those described above.

(3S,4R,5R, α R)-5-(Methanesulfonyloxy)-3,7-N-(α -methylbenzyl)imino-4-heptanolactone **43.** MsCl (47 μL , 61 mmol) was added dropwise to a stirred solution of **36** (100 mg, 0.38 mmol, >99:1 dr) and Et_3N (107 μL , 0.77 mmol) in CH_2Cl_2 (1.6 mL) at 0 °C. The resultant mixture was stirred at rt for 1 h, and then washed with saturated aq CuSO_4 (3 \times 2 mL), dried, and concentrated in vacuo. Purification via flash column chromatography (eluent CH_2Cl_2) gave **43** as a yellow oil (99 mg, 77%, >99:1 dr): $[\alpha]_{\text{D}}^{20} + 55.2$ (c 0.5, CHCl_3); ν_{max} (ATR) 1784 (C=O); δ_{H} (500 MHz, CDCl_3) 1.41 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.87–1.94 (1H, m, C(6) H_{A}), 2.24 (1H, app dtd, $J = 13.0, 5.1, 2.5$ Hz, C(6) H_{B}), 2.30 (1H, dd, $J = 16.9, 7.1$ Hz, C(2) H_{A}), 2.54–2.64 (2H, m, C(2) H_{B} , C(7) H_{A}), 2.97 (1H, app dt, $J = 12.3, 4.2$ Hz, C(7) H_{B}), 3.08 (3H, s, SO_2Me), 3.64 (1H, q, $J = 6.6$ Hz, C(α)H), 3.72–3.77 (1H, m, C(3)H), 4.39 (1H, app t, $J = 7.1$ Hz, C(4)H), 4.59 (1H, ddd, $J = 10.7, 7.1, 5.1$ Hz, C(5)H), 7.27–7.41 (5H, m, Ph); δ_{C} (125 MHz, CDCl_3) 20.8 (C(α)Me), 27.4 (C(2)), 29.9 (C(6)), 38.6 (SO_2Me), 39.5 (C(7)), 56.6 (C(3)), 61.1 (C(α)), 78.2 (C(4)), 80.1 (C(5)), 127.0, 128.8, 129.7 (*o,m,p*-Ph), 142.2 (*i*-Ph), 174.0 (C(1)); m/z (ESI⁺) 340 ([M + H]⁺, 100%); HRMS (ESI⁺) $\text{C}_{16}\text{H}_{21}\text{NNO}_5\text{S}^+$ ([M + Na]⁺) requires 362.1033, found 362.1041.

Methyl (2'S,3'R,4'S, α R)-2-[N(1')-(α -Methylbenzyl)-3',4'-epoxypiperidin-2'-yl]ethanoate **44.** Method A (from **16**). (CF_3CO)₂O (0.21 mL, 1.54 mmol) was added to a stirred solution of UHP (543 mg, 5.78 mmol) and CH_2Cl_2 (1.5 mL) at 0 °C, and the resultant mixture was stirred at 0 °C for 30 min. A solution of **16** (100 mg, 0.39 mmol, >99:1 dr) and $\text{CF}_3\text{CO}_2\text{H}$ (72 μL , 0.96 mmol) in CH_2Cl_2 (1.5 mL) was then added, and the resultant mixture was stirred at rt for 16 h. Saturated aq Na_2SO_3 (2 mL) was then added until starch iodide paper indicated no remaining oxidant. CH_2Cl_2 (5 mL) was added, and the organic layer was washed with 2.0 M aq NaOH (2 \times 5 mL). The combined aqueous layers were then extracted with CH_2Cl_2 (2 \times 10 mL), and the combined organic extracts were dried and concentrated in vacuo to give a 63:37 mixture of **36** and **44**, respectively. Purification via flash column chromatography (eluent $\text{CHCl}_3/\text{PrOH}$, 95:5) gave **36** as a yellow oil (30 mg, 34%, >99:1 dr). Further elution gave **44** as a yellow oil (14 mg, 13%, >99:1 dr): $[\alpha]_{\text{D}}^{20} + 6.5$ (c 1.0, CHCl_3); ν_{max} (ATR) 2976 (C—H), 1734 (C=O); δ_{H} (400 MHz, CDCl_3) 1.34 (3H, d, $J = 6.6$ Hz, C(α)Me), 1.56 (1H, dt, $J = 15.0, 1.7$ Hz, C(5') H_{A}), 1.88–1.96 (1H, m, C(5') H_{B}), 2.31–2.56 (1H, m, C(6') H_{A}), 2.52–2.56 (1H, m, C(6') H_{B}), 2.70 (2H, app d, $J = 7.3$ Hz, C(2) H_2), 3.26–3.28 (1H, m, C(3')H), 3.33–3.36 (1H, m, C(4')H), 3.71 (3H, s, OMe), 3.79 (1H, q, $J = 6.6$ Hz, C(α)H), 3.88 (1H, app q, $J = 6.1$ Hz, C(2')H), 7.21–7.50 (5H, m, Ph); δ_{C} (100 MHz, CDCl_3) 20.6 (C(5')), 22.4 (C(α)Me), 34.3 (C(2)), 36.3 (C(6')), 49.4 (C(2')), 51.5 (OMe), 52.0 (C(3')), 52.3 (C(4')), 58.4 (C(α)), 127.0, 127.1, 128.4 (*o,m,p*-Ph), 144.9 (*i*-Ph), 172.7 (C(1)); m/z (ESI⁺) 276 ([M + H]⁺, 100%); HRMS (ESI⁺) $\text{C}_{16}\text{H}_{22}\text{NO}_3^+$ ([M + H]⁺) requires 276.1594, found 276.1592.

Method B (from 43). K_2CO_3 (200 mg, 1.47 mmol) was added to a stirred solution of **43** (90 mg, 0.29 mmol, >99:1 dr) in MeOH (1 mL). The resultant mixture was stirred at rt for 16 h and then concentrated in vacuo. The residue was partitioned between CH_2Cl_2 (2 mL) and H_2O (2 mL), and the aqueous layer was extracted with CH_2Cl_2 (3×2 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent $CHCl_3/PrOH$, 95:5) gave **44** as a yellow oil (26 mg, 36%, >99:1 dr), which displayed characterization data consistent with those described above.

(2',5,3',R,4'R)-2-(3',4'-Dihydroxypiperidin-2'-yl)ethanoic Acid 46. $Pd(OH)_2/C$ (50% w/w of substrate, 8 mg) was added to a stirred solution of **36** (15 mg, 54 μ mol, >99:1 dr) in degassed EtOAc (0.2 mL). The resultant suspension was placed under H_2 (5 atm) and stirred vigorously at rt for 48 h. The reaction mixture was then filtered through a short plug of Celite (eluent EtOAc) and concentrated in vacuo to give **45** as a yellow oil (9 mg, quant, >99:1 dr). The residue was dissolved in H_2O (0.5 mL), and the resultant solution was allowed to stand at rt for two days before being concentrated in vacuo to give **46** as a white solid (9 mg, quant, >99:1 dr): mp 219–224 °C dec; $[\alpha]_D^{20} + 3.8$ (c 0.5, H_2O); ν_{max} (ATR) 3313 (O—H), 2943 (C—H), 1583 (zwitterionic β -amino acid); δ_H (500 MHz, D_2O) 1.78 (1H, app dd, $J = 15.3, 3.2$ Hz, $C(5')H_A$), 2.13 (1H, dddd, $J = 15.3, 12.7, 5.7, 3.0$ Hz, $C(5')H_B$), 2.48–2.59 (2H, m, $C(2)H_2$), 3.20–3.33 (2H, m, $C(6')H_2$), 3.71–3.73 (1H, m, $C(2')H$), 3.80 (1H, app d, $J = 3.9$ Hz, $C(3')H$), 4.00 (1H, app q, $J = 3.0$ Hz, $C(4')H$); δ_C (125 MHz, D_2O) 23.5 ($C(5')$), 38.4 ($C(2)$), 39.0 ($C(6')$), 52.6 ($C(2')$), 65.1 ($C(4')$), 67.4 ($C(3')$), 177.4 ($C(1)$); m/z (ESI^+) 176 ($[M + H]^+$, 100%); HRMS (ESI^+) $C_7H_{13}NNaO_4^+$ ($[M + Na]^+$) requires 198.0737, found 198.0740.

(2R,3S,4R,5R, α R)-2,5-Dihydroxy-3,7-N-(α -methylbenzyl)-imino-4-heptanolactone 47 and (R,R,R,R)-2-Hydroxy-2-[N(1')-(α -methylbenzyl)-3',4'-dihydroxypiperidin-2'-yl]-ethanoic Acid 50. **Method A (from 15).** HBf_4 (48% aq, 0.32 mL, 2.45 mmol) was added to a stirred solution of **15** (136 mg, 0.49 mmol, >99:1 dr) in CH_2Cl_2 (1.4 mL) at rt, and the resultant mixture was stirred at rt for 5 min. *m*-CPBA (75%, 451 mg, 1.96 mmol) was then added, and the resultant mixture was stirred at rt for 48 h. A mixture of $CHCl_3/PrOH$ (3:1, 5 mL) was then added, and the organic layer was washed with saturated aq Na_2SO_3 (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was then washed with saturated aq $NaHCO_3$ (5 mL), and the combined aqueous washings were extracted with $CHCl_3/PrOH$ (3:1, 3×10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent $CHCl_3/PrOH$, 95:5) gave **47** as a white solid (56 mg, 47%, >99:1 dr): mp 235–241 °C dec; $[\alpha]_D^{20} + 42.0$ (c 1.0, $CHCl_3$); ν_{max} (ATR) 3505 (O—H), 1763 (C=O); δ_H (400 MHz, $CDCl_3$) 1.42 (3H, d, $J = 6.6$ Hz, $C(\alpha)Me$), 1.58 (1H, app dtd, $J = 13.2, 9.4, 3.6$ Hz, $C(6)H_A$), 1.88–1.93 (1H, m, $C(6)H_B$), 2.73 (1H, ddd, $J = 11.1, 6.7, 3.6$ Hz, $C(7)H_A$), 3.06 (1H, ddd, $J = 11.1, 9.4, 2.8$ Hz, $C(7)H_B$), 3.36 (1H, app t, $J = 5.5$ Hz, $C(3)H$), 3.96 (1H, ddd, $J = 9.4, 6.7, 4.3$ Hz, $C(5)H$), 4.15 (1H, app t, $J = 6.7$ Hz, $C(4)H$), 4.27 (1H, d, $J = 5.5$ Hz, $C(2)H$), 4.40 (1H, q, $J = 6.6$ Hz, $C(\alpha)H$), 7.16–7.37 (5H, m, *Ph*); δ_C (100 MHz, $CDCl_3$) 21.2 ($C(\alpha)Me$), 31.6 ($C(6)$), 42.6 ($C(7)$), 59.4 ($C(3)$), 61.1 ($C(\alpha)$), 69.8 ($C(5)$), 72.2 ($C(2)$), 82.8 ($C(4)$), 128.4, 129.0, 129.5 (*o,m,p-Ph*), 144.3 (*i-Ph*), 178.2 ($C(1)$); m/z (ESI^+) 278 ($[M + H]^+$, 100%); HRMS (ESI^+) $C_{15}H_{19}NNaO_4^+$ ($[M + Na]^+$) requires 300.1206, found 300.1198. Further elution gave **50** as colorless oil (25 mg, 20%, >99:1 dr): $[\alpha]_D^{20} - 18.9$ (c 1.0, $CHCl_3$); ν_{max} (ATR) 3351 (O—H), 1611 (C=O); δ_H (400 MHz, MeOH- d_4) 1.65 (1H, app dd, $J = 14.5, 3.1$ Hz, $C(5')H_A$), 1.80 (3H, d, $J = 6.5$ Hz, $C(\alpha)Me$), 2.31–2.39 (1H, m, $C(5')H_B$), 2.82 (1H, app td, $J = 12.4, 3.1$ Hz, $C(6')H_A$), 3.38 (1H, app dt, $J = 12.4, 3.7$ Hz, $C(6')H_B$), 3.67 (1H, dd, $J = 3.8, 2.2$ Hz, $C(2')H$), 3.73 (1H, app q, $J = 3.7$ Hz, $C(4')H$), 3.97–3.99 (1H, m, $C(3')H$), 4.84 (1H, d, $J = 3.8$ Hz, $C(2)H$), 5.14 (1H, q, $J = 6.5$ Hz, $C(\alpha)H$), 7.46–7.67 (5H, m, *Ph*); δ_C (100 MHz, MeOH- d_4) 17.6 ($C(\alpha)Me$), 26.0 ($C(5')$), 43.2 ($C(6')$), 61.8 ($C(\alpha)$), 62.1 ($C(2')$), 66.3 ($C(4')$), 71.9 ($C(3')$), 72.2 ($C(2)$), 130.4, 130.9, 131.4 (*o,m,p-Ph*), 134.5 (*i-*

Ph), 176.8 ($C(1)$); m/z (ESI^+) 296 ($[M + H]^+$, 100%); HRMS (ESI^+) $C_{15}H_{21}NNaO_4^+$ ($[M + Na]^+$) requires 318.1312, found 318.1317.

Method B (from 15). $TsOH \cdot H_2O$ (267 mg, 1.57 mmol) was added to a stirred solution of **15** (100 mg, 0.32 mmol, >99:1 dr) in CH_2Cl_2 (1 mL) at rt, and the resultant mixture was stirred at rt for 5 min. *m*-CPBA (75%, 290 mg, 1.26 mmol) was then added, and the resultant mixture was stirred at rt for 48 h. A mixture of $CHCl_3/PrOH$ (3:1, 3 mL) was then added, and the organic layer was washed with saturated aq Na_2SO_3 (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was washed with saturated aq $NaHCO_3$ (5 mL), and the combined aqueous layers were extracted with $CHCl_3/PrOH$ (3:1, 3×10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent $CHCl_3/PrOH$, 95:5) gave **47** as a white solid (20 mg, 23%, >99:1 dr), which displayed characterization data consistent with those described above.

Method C (from 17). HBf_4 (48% aq, 240 μ L, 1.81 mmol) was added to a stirred solution of **17** (100 mg, 0.36 mmol, >99:1 dr) in CH_2Cl_2 (1 mL) at rt, and the resultant mixture was stirred at rt for 5 min. *m*-CPBA (75%, 334 mg, 1.45 mmol) was then added, and the resultant mixture was stirred at rt for 48 h. A mixture of $CHCl_3/PrOH$ (3:1, 2 mL) was then added, and the organic layer was washed with saturated aq Na_2SO_3 (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was washed with saturated aq $NaHCO_3$ (5 mL), and the combined aqueous layers were extracted with $CHCl_3/PrOH$ (3:1, 3×10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent $CHCl_3/PrOH$, 95:5) gave **47** as a white solid (20 mg, 20%, >99:1 dr), which displayed characterization data consistent with those described above.

Method D (from 15). CCl_3CO_2H (129 mg, 0.79 mmol) was added to a stirred solution of **15** (50 mg, 0.16 mmol, >99:1 dr) in CH_2Cl_2 (0.5 mL) at rt, and the resultant mixture was stirred at rt for 5 min. *m*-CPBA (75%, 145 mg, 0.63 mmol) was then added, and the reaction mixture was stirred at rt for 48 h. $CHCl_3/PrOH$ (3:1, 5 mL) was then added, and the organic layer was washed with saturated aq Na_2SO_3 (5 mL) until starch iodide paper indicated no remaining oxidant. The organic layer was then washed with saturated aq $NaHCO_3$ (5 mL), and the combined aqueous washings were extracted with $CHCl_3/PrOH$ (3:1, 3×10 mL). The combined organic extracts were then dried and concentrated in vacuo. Purification via flash column chromatography (eluent $CHCl_3/PrOH$, 95:5) gave an 87:13 mixture of **47** and **48**, respectively, as a colorless oil (13 mg). Data for **48**: δ_H (400 MHz, $CDCl_3$) [selected peaks] 1.39 (9H, s, CM_e_3), 1.52 (3H, m, $C(\alpha)Me$), 1.88–1.91 (1H, m, $C(5')H_A$), 2.32–2.38 (2H, m, $C(6')H_2$), 2.91–2.94 (1H, m, $C(5')H_B$), 3.58–3.66 (2H, m, $C(2')H$, $C(3')H$), 4.53 (1H, d, $J = 4.1$ Hz, $C(2)H$), 4.60–4.66 (1H, m, $C(4')H$), 7.17–7.37 (5H, m, *Ph*); the characterization data for **47** were consistent with those described above.

(R,R,R,R)-2-Hydroxy-2-(3',4'-dihydroxypiperidin-2'-yl)-ethanoic Acid 51. **Method A (from 50).** $Pd(OH)_2/C$ (50% w/w of substrate, 10 mg) was added to a stirred solution of **50** (20 mg, 0.14 mmol, >99:1 dr) in degassed MeOH (0.5 mL). The resultant suspension was placed under H_2 (1 atm) and stirred vigorously at rt for 12 h. The reaction mixture was then filtered through a short plug of Celite (eluent MeOH) and concentrated in vacuo to give **51** as a colorless oil (13 mg, quant, >99:1 dr): $[\alpha]_D^{20} - 19.3$ (c 0.4, H_2O); ν_{max} (ATR) 3320 (O—H), 2944 (C—H), 1448 (zwitterionic β -amino acid); δ_H (500 MHz, D_2O) 1.77 (1H, dd, $J = 15.3, 2.7$ Hz, $C(5')H_A$), 2.14–2.22 (1H, m, $C(5')H_B$), 3.27–3.29 (2H, m, $C(6')H_2$), 3.60 (1H, dd, $J = 6.8, 1.4$ Hz, $C(2')H$), 3.98 (1H, app q, $J = 3.4$ Hz, $C(4')H$), 4.04 (1H, app d, $J = 3.4$ Hz, $C(3')H$), 4.19 (1H, d, $J = 6.8$ Hz, $C(2)H$); δ_C (125 MHz, D_2O) 23.3 ($C(5')$), 39.5 ($C(6')$), 55.3 ($C(2')$), 64.9 ($C(4')$), 66.2 ($C(3')$), 69.7 ($C(2)$), 176.8 ($C(1)$); m/z (ESI^+) 192 ($[M + H]^+$, 100%); HRMS (ESI^+) $C_7H_{14}NO_5^+$ ($[M + H]^+$) requires 192.0866, found 192.0869.

Method B (from 47). $Pd(OH)_2/C$ (50% w/w of substrate, 25 mg) was added to a stirred solution of **47** (50 mg, 0.18 mmol, >99:1 dr) in degassed MeOH (1 mL). The resultant suspension was placed under H_2 (1 atm) and stirred vigorously at rt for 12 h. The reaction mixture

was then filtered through a short plug of Celite (eluent MeOH) and concentrated in vacuo to give **52** as a colorless oil (31 mg, quant, >99:1 dr). The residue was dissolved in H₂O (0.5 mL), and the resultant solution was allowed to stand at rt for two days before being concentrated in vacuo to give **51** as a colorless oil (31 mg, quant, >99:1 dr): $[\alpha]_{\text{D}}^{20} - 14.2$ (c 0.5, H₂O).

■ ASSOCIATED CONTENT

■ Supporting Information

Copies of ¹H and ¹³C NMR spectra and crystallographic information files (structures CCDC 1001521–1001526). This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: steve.davies@chem.ox.ac.uk

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Astra-Zeneca for a studentship (K.C.).

■ REFERENCES

- (1) Magalhaes, A. F.; Santos, C. C.; Magalhaes, E. G.; Nogueira, M. A. *Phytochem. Anal.* **2002**, *13*, 215.
- (2) Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R. J. *Phytochemistry* **2001**, *56*, 265.
- (3) Formica, J. V.; Katz, E. J. *Biol. Chem.* **1973**, *248*, 2066.
- (4) (a) Wall, K. A.; Pierce, J. D.; Elbein, A. D. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 5644. (b) Sinot, M. L. *Chem. Rev.* **1990**, *90*, 1171. (c) Winchester, B.; Fleet, G. W. J. *Glycobiology* **1992**, *2*, 199. (d) Goss, P. E.; Reid, C. L.; Bailey, D.; Dennis, J. W. *Clin. Cancer Res.* **1997**, *3*, 11077. (e) Bols, M. *Acc. Chem. Res.* **1998**, *31*, 1. (f) Heightman, T. D.; Vasella, A. *Angew. Chem., Int. Ed.* **1999**, *38*, 750. (g) Zechel, D. L.; Withers, S. G. *Acc. Chem. Res.* **2000**, *33*, 11. (h) Lopez, M. D.; Cobo, J.; Nogueras, M. *Curr. Org. Chem.* **2008**, *12*, 718. (i) D'Alonzo, D.; Guaragna, A.; Palumbo, G. *Curr. Med. Chem.* **2009**, *16*, 473. (j) Gloster, T. M.; Davies, G. J. *Org. Biomol. Chem.* **2010**, *8*, 305. (k) Aguilar-Moncayo, M.; García-Moreno, M. I.; Trapero, A.; Egado-Gabás, M.; Llebaria, A.; Fernández, J. M. G.; Mellet, C. O. *Org. Biomol. Chem.* **2011**, *9*, 3698. (l) Horne, G.; Wilson, F. X. *Prog. Med. Chem.* **2011**, *50*, 135. (m) Nash, R. J.; Kato, A.; Yu, C. Y.; Fleet, G. W. J. *Future Med. Chem.* **2011**, *3*, 1513. (n) Ayers, B. J.; Ngo, N.; Jenkinson, S. F.; Martínez, R. F.; Shimada, Y.; Adachi, I.; Weymouth-Wilson, A. C.; Kato, A.; Fleet, G. W. J. *J. Org. Chem.* **2012**, *77*, 7777.
- (5) (a) Okamoto, S.; Hijikata, A.; Kikumoto, R.; Tonomura, S.; Hara, H.; Ninomiya, K.; Maruyama, A.; Sugano, M.; Tamao, Y. *Biochem. Biophys. Res. Commun.* **1981**, *101*, 440. (b) Ornstein, P. L.; Shaus, J. M.; Chambers, J. W.; Huser, D. L.; Lueander, J. D.; Wong, D. T.; Paschal, J. W.; Jones, N. D.; Deeter, J. B. *J. Med. Chem.* **1989**, *32*, 827. (c) Bruce, I.; Fleet, G. W. J.; Cenci di Bello, I.; Winchester, B. *Tetrahedron* **1992**, *48*, 10191.
- (6) (a) Copeland, T. D.; Wondrak, E. M.; Toszer, J.; Roberts, M. M.; Oraszán, S. *Biochem. Biophys. Res. Commun.* **1990**, *169*, 310. (b) McNaughton-Smith, G.; Hanessian, S.; Lombart, H. G.; Lubell, W. D. *Tetrahedron* **1997**, *53*, 12789. (c) Quibell, M.; Benn, A.; Flinn, N.; Monk, T.; Ramjee, M.; Wang, Y.; Watts, J. *Bioorg. Med. Chem.* **2004**, *12*, 5689.
- (7) (a) Bagal, S. K.; Davies, S. G.; Lee, J. A.; Roberts, P. M.; Scott, P. M.; Thomson, J. E. *J. Org. Chem.* **2010**, *75*, 8133. (b) Bagal, S. K.; Davies, S. G.; Fletcher, A. M.; Lee, J. A.; Roberts, P. M.; Scott, P. M.; Thomson, J. E. *Tetrahedron Lett.* **2011**, *52*, 2216. (c) Csatayová, K.; Davies, S. G.; Lee, J. A.; Roberts, P. M.; Russell, A. J.; Thomson, J. E.; Wilson, D. L. *Org. Lett.* **2011**, *13*, 2606. (d) Csatayová, K.; Davies, S. G.; Ford, J. G.; Lee, J. A.; Roberts, P. M.; Thomson, J. E. *J. Org. Chem.* **2013**, *78*, 12397. (e) Davies, S. G.; Figgucchia, A. L. A.; Fletcher, A. M.; Roberts, P. M.; Thomson, J. E. *Org. Lett.* **2013**, *15*, 2042. (f) Davies, S. G.; Fletcher, A. M.; Foster, E. M.; Lee, J. A.; Roberts, P. M.; Thomson, J. E.; Waul, M. A. *Tetrahedron* **2014**, *70*, 7106.
- (8) For a review of this methodology, see: Davies, S. G.; Fletcher, A. M.; Roberts, P. M.; Thomson, J. E. *Tetrahedron: Asymmetry* **2012**, *23*, 1111.
- (9) VanRheenen, V.; Kelly, R. C.; Cha, D. Y. *Tetrahedron Lett.* **1976**, *17*, 1973.
- (10) (a) Donohoe, T. J.; Moore, P. R.; Waring, M. J.; Newcombe, N. J. *Tetrahedron Lett.* **1997**, *38*, 5027. (b) Donohoe, T. J.; Blades, K.; Moore, P. R.; Winter, J. J. G.; Helliwell, M.; Stemp, G. J. *Org. Chem.* **1999**, *64*, 2980. (c) Donohoe, T. J. *Synlett* **2002**, 1223. (d) Donohoe, T. J.; Blades, K.; Moore, P. R.; Waring, M. J.; Winter, J. J. G.; Helliwell, M.; Newcombe, N. J.; Stemp, G. J. *Org. Chem.* **2002**, *67*, 7946.
- (11) For a review of this methodology, see: Davies, S. G.; Fletcher, A. M.; Thomson, J. E. *Org. Biomol. Chem.* **2014**, *12*, 4544.
- (12) Davies, S. G.; Foster, E. M.; McIntosh, C. R.; Roberts, P. M.; Rosser, T. E.; Smith, A. D.; Thomson, J. E. *Tetrahedron: Asymmetry* **2011**, *22*, 1035 and references therein.
- (13) Davies, S. G.; Fletcher, A. M.; Roberts, P. M.; Smith, A. D. *Tetrahedron* **2008**, *65*, 10192.
- (14) Costello, J. F.; Davies, S. G.; Ichihara, O. *Tetrahedron: Asymmetry* **1994**, *5*, 1999.
- (15) Bunnage, M. E.; Chernega, A. N.; Davies, S. G.; Goodwin, C. J. *J. Chem. Soc., Perkin Trans. 1* **1994**, 2373.
- (16) Davies, S. G.; Fletcher, A. M.; Foster, E. M.; Lee, J. A.; Roberts, P. M.; Thomson, J. E. *J. Org. Chem.* **2013**, *78*, 2500.
- (17) Crystallographic data (excluding structure factors) for the structures of **21**·H₂O, **23**, **37**, **39**, **46**, and **47** have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 1001521–1001526, respectively.
- (18) (a) Flack, H. D. *Acta Crystallogr.* **1983**, *A39*, 876. (b) Flack, H. D.; Bernardinelli, G. *Acta Crystallogr.* **1999**, *A55*, 908. (c) Flack, H. D.; Bernardinelli, G. *J. Appl. Crystallogr.* **2000**, *33*, 1143.
- (19) Fleet, G. W. J.; Son, J. C. *Tetrahedron* **1988**, *44*, 2637.
- (20) For examples of previous syntheses of fagomine and its stereoisomers, see: (a) Fleet, G. W. J.; Smith, P. W. *Tetrahedron Lett.* **1985**, *26*, 1469. (b) Degiorgis, F.; Lombardo, M.; Trombini, C. *Synthesis* **1997**, 1243. (c) Désiré, J.; Dransfield, P. J.; Gore, P. M.; Shipman, M. *Synlett* **2001**, 1329. (d) Banba, Y.; Abe, C.; Nemoto, H.; Kato, A.; Adachi, I.; Takahata, H. *Tetrahedron: Asymmetry* **2001**, *12*, 817. (e) Takahata, H.; Banba, Y.; Ouchi, H.; Nemoto, H.; Kato, A.; Adachi, I. *J. Org. Chem.* **2003**, *68*, 3603. (f) Castillo, J. A.; Calveras, J.; Casas, J.; Mitjans, M.; Vinardell, M. P.; Parella, T.; Inoue, T.; Sprenger, G. A.; Joglar, J.; Clapés, P. *Org. Lett.* **2006**, *8*, 6067. (g) Sugiyama, M.; Hong, Z.; Liang, P.-H.; Dean, S. M.; Whalen, L. J.; Greenberg, W. A.; Wong, C.-H. *J. Am. Chem. Soc.* **2007**, *129*, 14811. (h) Yokoyama, H.; Ejiri, H.; Miyazawa, M.; Yamaguchi, S.; Hirai, Y. *Tetrahedron: Asymmetry* **2007**, *18*, 852. (i) Bartali, L.; Scarpi, D.; Guarna, A.; Prandi, C.; Occhiato, E. G. *Synlett* **2009**, 913. (j) Bartali, L.; Casini, A.; Guarana, A.; Occhiato, E. G.; Scarpi, D. *Eur. J. Org. Chem.* **2010**, 5831. (k) Kim, J.-Y.; Mua, Y.; Jin, X.; Park, S.-H.; Pham, V.-T.; Song, D.-K.; Lee, K.-Y.; Hama, W.-H. *Tetrahedron* **2011**, *67*, 9426. (l) Kundu, P. K.; Ghosh, S. K. *Tetrahedron: Asymmetry* **2011**, *22*, 1090. (m) Babich, L.; van Hemert, L. J. C.; Bury, A.; Hartog, A. F.; Falcicchio, P.; van der Oost, J.; van Herk, T.; Wever, R.; Rutjes, F. P. J. T. *Green Chem.* **2011**, *13*, 2895.
- (21) Kato, A.; Asano, N.; Kizu, H.; Matsui, K. *J. Nat. Prod.* **1997**, *60*, 312.
- (22) Hanson, K. R. *J. Am. Chem. Soc.* **1966**, *88*, 2731.
- (23) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. *Organometallics* **1996**, *15*, 1518.
- (24) Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, C. K.; Watkin, D. J. *J. Appl. Crystallogr.* **2003**, *36*, 1487.
- (25) Karoyan, P.; Chassaing, G. *Tetrahedron: Asymmetry* **1997**, *8*, 2025.
- (26) DuBois, D. L.; Miedaner, A. *J. Am. Chem. Soc.* **1987**, *109*, 113.